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aa-IPI  age-adjusted International Prognostic Index 
ABC  activated B-cell-like 
ASCT  autologous stem cell transplantation  
BCL2/6  B-cell leukemia/lymphoma 2/6 
BEAC  carmustine, etoposide, cytarabine and cyclophosphamide 
BEAM  carmustine, etoposide, cytarabine and melphalan 
CCL3  chemokine ligand 3 
CCND2  cyclin D2 
CD  cluster of differentiation 
cDNA  complementary deoxyribonucleic acid 
CHOEP cyclophosphamide, doxorubicin, vincristine, etoposide and 
prednisone 
CHOP  cyclophosphamide, doxorubicin, vincristine and prednisone 
CI  confidence interval 
CLL  chronic lymphocytic leukaemia 
CNOP  cyclophosphamide, mitoxantrone, vincristine and prednisone 
CNS  central nervous system 
CT  chemotherapy 
DLBCL  diffuse large B-cell lymphoma 
DNA  deoxyribonucleic acid 
EBV  Epstein-Barr virus 
ECOG  Eastern Cooperative Oncology Group 
EFS  event-free survival 
EPOCH etoposide, prednisone, vincristine, cyclophosphamide and 
doxorubicin 
18FFDG-PET positron emission tomography with fluorine-18 
fluorodeoxyglocose 
FFS  failure-free survival 
FL  follicular lymphoma  
FN1  fibronectin 1 
FOXP1/3  forkhead box protein 1/3 
GC  germinal centre 
GCB  germinal centre B-cell-like 
GCET1  germinal centre B-cell-expressed transcript 1 
GELA  Groupe d’Etude des Lymphomes de l’Adulte 
GEP  gene expression profiling 
HDT  high-dose chemotherapy 
ICAM-1  intracellular adhesion molecule 1 
ICT  immunochemotherapy 
Ig  immunoglobulin 
IHC  immunohistochemistry 
IL-2/4/6/10  interleukin 2/4/6/10 
IPI  International Prognostic Index 






LDH  lactate dehydrogenase 
LMO2  LIM domain only 2 
MACOP-B methotrexate, doxorubicin, cyclophosphamide, vincristine, 
prednisone and bleomycin 
MALT  mucosa-associated lymphoid tissue 
MHC  major histocompatibility complex 
MInT  MabThera International Trial 
mRNA  messenger ribonucleic acid 
MUM1/IRF4  multiple myeloma 1 / interferon regulatory factor 4 
NF-κB  nuclear factor kappa B 
NHL  non-Hodgkin lymphoma 
NK  natural killer  
non-GCB  non-germinal centre B-cell-like 
OS  overall survival 
PFS  progression-free survival 
PKC  protein kinase C 
PMLBCL  primary mediastinal large B-cell lymphoma 
PRDM1β  positive regulatory domain I β 
R  rituximab 
RICOVER-60 rituximab with CHOP in patients aged over 60 years-trial 
R-IPI  revised International Prognostic Index 
RNA  ribonucleic acid 
TMA  tissue microarray 
TNF tumour necrosis factor 
VACOP etoposide, doxorubicin, cyclophosphamide, vincristine and 
prednisone 
VACOP-B  etoposide, doxorubicin, cyclophosphamide, vincristine, 
prednisone and bleomycin    
VEGF  vascular endothelial growth factor 









Diffuse large B-cell lymphoma (DLBCL) is a cancer originating from the lymphatic 
tissue. It is the most common of the non-Hodgkin lymphomas. As DLBCL is 
characterized by heterogeneous clinical and biological features, its prognosis varies.  
 
To date, the International Prognostic Index (IPI) has been the strongest predictor of 
outcome for DLBCL patients and the strongest determinant of a given therapy. However, 
IPI risk stratification is based on clinical features, and no biological characters of the 
disease are taken into account. Although knowledge of DLBCL biology has increased, 
many aspects remain unclear. Gene expression profiling studies have identified two major 
cell-of-origin phenotypes in DLBCL with different prognoses; the favourable germinal 
centre B-cell-like (GCB) and the unfavourable activated B-cell-like (ABC) subgroups. By 
using immunohistochemistry, identification of the GCB and ABC phenotypes has been 
translated into a clinically applicable approach, defining the subgroups as GCB and non-
GCB, respectively. However, results of the prognostic impact of the 
immunohistochemically defined GCB and non-GCB distinction are controversial, and a 
molecular classification of DLBCL is not readily applicable in daily clinical practice. 
Furthermore, since the addition of the CD20 antibody rituximab to chemotherapy has been 
established as the standard treatment of DLBCL, all molecular markers need to be 
evaluated in the post-rituximab era of lymphoma therapies. 
 
In this study, we aimed to evaluate the predictive value of immunohistochemically defined 
cell-of-origin classification in DLBCL patients. The GCB and non-GCB phenotypes were 
defined according to the Hans algorithm based on the expression of CD10, BCL6 and 
MUM1/IRF4 among 90 immunochemotherapy- and 104 chemotherapy-treated DLBCL 
patients. In the chemotherapy group, we observed a significant difference in survival 
between GCB and non-GCB patients, who had a good and a poor prognosis, respectively. 
However, in the rituximab group, no prognostic value of the GCB phenotype was 
observed. Likewise, among 29 high-risk de novo DLBCL patients receiving high-dose 
chemotherapy and autologous stem cell transplantation, the survival of non-GCB patients 
was improved, but no difference in outcome was seen between GCB and non-GCB 
subgroups. In contrast, the predictive value of the classification remained in the control 
group, which consisted of 34 high-risk DLBCL patients treated with conventional 
chemotherapy. 
 
Similarly, the results of the individual predictive molecular markers transcription factor 






immunochemotherapy-treated DLBCL patients. The markers were evaluated in a cohort of 
117 patients treated with rituximab and antracylin-based chemotherapy. Positive FOXP1 
expression was observed in 19% of patients, whereas 67% of patients were BCL2-
positive. FOXP1 expression could not distinguish between patients, with favourable and 
those with poor outcomes. In contrast, BCL2-negative DLBCL patients had significantly 
superior survival relative to BCL2-positive patients. The prognostic impact of BCL2 was 
primarily observed in the non-GCB subgroup.  
 
Since the results suggested that the Hans algorithm based on the expression of CD10, 
BCL6 and MUM1/IRF4 was not applicable in immunochemotherapy-treated DLBCL 
patients, we aimed to further focus on algorithms based on ABC markers. The germinal 
centre marker BCL6 was omitted from the algorithm because of reported weaknesses in 
the reproducibility of the staining. We examined the modified activated B-cell-like 
algorithm based on MUM1/IRF4 and FOXP1 expressions, as well as a previously reported 
Muris algorithm based on the expression of BCL2, CD10 and MUM1/IRF4 among 88 
DLBCL patients uniformly treated with immunochemotherapy. Both algorithms 
distinguished the unfavourable ABC-like subgroup with a significantly inferior failure-
free survival relative to the GCB-like DLBCL patients. 
 
Taken together, our results indicate that the immunohistochemically defined cell-of-origin 
classification in DLBCL has a prognostic impact in the immunochemotherapy era, when 
the identifying algorithms are based on ABC-associated markers. We also propose that 
BCL2 negativity is predictive of a favourable outcome. Further investigational efforts are, 
however, warranted to identify the molecular features of DLBCL that could enable 







The incidence of cancer is increasing worldwide. In 2007, about 26 000 people received a 
cancer diagnosis in Finland (Finnish Cancer Registry 2008). Of these, approximately 1000 
(4%) were non-Hodgkin lymphomas (NHLs).   
 
Diffuse large B-cell lymphoma (DLBCL) is the largest NHL entity. The clinical course of 
the disease is aggressive and patients are often symptomatic. An immediate initiation of 
treatment is required. The combination of the CD20 antibody rituximab with multi-agent 
chemotherapy has become the standard of care for de novo DLBCL patients in the 2000s. 
The addition of rituximab to chemotherapy has improved survival relative to conventional 
chemotherapy, and currently more than half of the patients can be cured (Coiffier et al. 
2002). 
 
The International Prognostic Index (IPI) is a standard approach to estimate prognosis in 
DLBCL (International Non-Hodgkin´s Lymphoma Prognostic Factor Project 1993). Five 
clinical parameters, including age, disease distribution, performance status, lactate 
dehydrogenase (LDH) level and involvement of extranodal sites, distinguish between 
cases with good and poor outcomes. Although the survival of DLBCL patients has 
improved, some patients experience relapse or have refractory disease and ultimately die 
from their lymphoma. In addition to the clinical features of the disease, the heterogeneous 
biology of DLBCL most likely influences the outcome. 
 
Gene expression profiling (GEP) studies have identified prognostic biological markers and 
phenotypes in DLBCL (Alizadeh et al. 2000, Rosenwald et al. 2002). The translation of 
the markers immunohistochemically is a clinically applicable approach with many 
expectations. This study has focused on evaluating immunohistochemically defined 
molecular markers and phenotypes in DLBCL patients treated with immunochemotherapy 







5. REVIEW OF THE LITERATURE 
5.1 General aspects of non-Hodgkin lymphomas and diffuse large B-cell 
lymphoma (DLBCL) 
NHLs are heterogeneous malignancies derived from lymphatic tissue. The World Health 
Organization (WHO) has classified the lymphoid neoplasms based on the Revised 
European American Lymphoma Classification of Lymphoid Neoplasms (REAL) 
(Swerdlow et al. 2008). The classification determines the lymphomas according to 
morphology, immunophenotype and genetic and clinical features. Three major categories 
of malignancies have been defined: B-cell NHLs, T-cell and NK-cell NHLs, and Hodgkin 
lymphomas.  
 
The incidence of NHLs has increased in the last decades. In Finland, 1050 new cases were 
diagnosed in 2007, accounting for about 4% of all malignancies (www.cancerregistry.fi). 
The NHLs were the sixth most frequent type of cancer in men and in women (incidence: 
men 12.0/100 000 and women 9.4/100 000). Similarly, in Sweden during the same time 
period the incidence of NHLs was 16.3/100 000 for men and 12.8/100 000 for women and 
1329 new lymphoma diagnoses were reported (www.socialstyrelsen.se).  
5.1.1 B-cell differentiation and neoplasms  
In general, naïve B-cells in the central lymphoid system mature through transformation 
and proliferation into antibody-producing plasma cells and memory B-cells. Malignancies 
may develop during this process, and consequently, B-cell neoplasms tend to imitate 
different stages of normal B-cell differentiation (Figure 1) (Swerdlow et al. 2008). 
 
In the primary phase of differentiation, the precursor B-cell undergoes immunoglobulin 
gene arrangement and either develops into a naïve B-cell in the peripheral lymphoid tissue 
or undergoes apoptosis. The naïve B-cell may enter the primary follicle, forming a 
germinal centre (GC), wherein it matures to a CD10- and BCL6-expressing centroblast. 
Centroblasts mature further into centrocytes, which later also re-express BCL2 (reviewed 
in MacLennan 1994). Additionally, the naïve B-cell may directly develop into a plasma 
cell.  Within the germinal centre, the downregulation of BCL6, partly by the action of the 
IRF4/MUM1 protein (Saito et al. 2007b), is essential for the differentiation of 
lymphocytes to plasma cells or memory B-cells. On the other hand, upon antigen 







According to the phases of B-cell differentiation, the precursor B-cell neoplasm includes 
B lymphoblastic leukaemia/lymphoma, whereas the pre-GC neoplasm comprises mantle 
cell lymphoma. Tumours of the GC B-cells are follicular lymphoma (FL), Burkitt 
lymphoma, Hodgkin lymphoma and DLBCL. In the last stage of B-cell differentiation, 
post-GC neoplasms develop, including marginal zone and mucosa-associated lymphoid 
tissue (MALT) lymphomas, lymphoplasmacytic lymphoma, chronic lymphocytic 
leukaemia (CLL), plasma cell myeloma and some cases of DLBCL. 
 
Post-GC neoplasms


























Precursor B-cells Peripheral B-cells
Germinal centre
 
Figure 1. Scheme of B-cell differentiation and corresponding B-cell neoplasms. Modified from 
Swerdlow et al. 2008. 
5.1.2 Mature B-cell neoplasms 
Mature B-cell neoplasms include about 30 different entities, forming the largest category 
(85%) of all NHLs. The DLBCL is the most common type of NHL, accounting for about 
35% of all NHLs, followed by FL (25-30%), MALT (5-10%) and mantle cell lymphoma 
(5%). The remaining one-third of NHLs contain minor B-cell and T-cell entities 
(Swerdlow et al. 2008). B-cell lymphomas are identified by a combination of 
morphological features and distinctive immunophenotypes.  
 
The median age for all mature B-cell neoplasms is about 65 years, and the risk of 






Acknowledged risk factors for lymphomas are abnormalities of the immune system, 
including primary and secondary immunodeficiencies. Immunodeficiency may be due to 
human immunodeficiency virus, transplantation-related immunosuppressive treatment or 
autoimmune disease (Kassan et al. 1978, Nalesnik et al. 1988, Beral et al. 1991). 
Infectious agents and chronic infections are also associated with NHLs, e.g. the relation 
between Epstein-Barr virus (EBV) and endemic Burkitt lymphoma (Prevot et al. 1992). 
 
Based on the clinical behaviour of NHLs, lymphomas can be divided into aggressive and 
indolent types (Hiddemann et al. 1996). Aggressive lymphomas have a rapid clinical 
course. The patients are symptomatic and appropriate treatment should be initiated 
immediately after diagnosis. Survival with aggressive lymphomas is shorter than with 
indolent entities, although about two of three DLBCL patients can be cured. The indolent 
types of NHLs, including FL, have a reasonably good prognosis, but advanced stages of 
the disease are, despite treatment, considered incurable.  
 
Figure 2. Diffuse large B-cell lymphoma lymph node. 1) Large centroblasts growing in a diffuse 
pattern (haematoxylin and eosin (H&E) stained). 2) Lymphoma B-cells have a high expression of 
CD20. 
5.1.3 Classification and pathogenesis of DLBCL 
The characteristic morphology of DLBCL is a diffuse proliferation pattern of large 
lymphocytes that have transformed the nodal structure of the lymph node (Figure 2A). 
The nuclear size of the lymphoid cell is about twice the size of a normal lymphocyte. The 
majority of DLBCLs arise from the normal antigen-driven B-cell in the germinal centre of 
the peripheral lymphoid organ (reviewed in Kuppers et al. 1999). According to the 






classification separates the lymphoma into several distinctive entities (Table 1). Three 
common morphological variants of DLBCL have been identified: centroblastic, 
immunoblastic and anaplastic. The molecular and immunohistochemical subgroups will 
be presented in detail in the forthcoming sections. Identification of the subtypes is not only 
based on morphological features but also on specific clinical presentations of the entities, 
like the primary DLBCL of the central nervous system (CNS) and the EBV-positive 
DLBCL of the elderly patients. Furthermore, those heterogeneous cases that are 
unclassified according to the criteria are acknowledged as a subgroup of DLBCL not 
otherwise specified (NOS). 
 
Table 1. Diffuse large B-cell lymphoma: variants, subgroups and subtypes according to the WHO 






















Diffuse large B-cell lymphoma, not otherwise specified (NOS) 




Rare morphologic variants 
Molecular subgroups 
 Germinal centre B-cell-like (GCB) 
 Activated B-cell-like (ABC) 
Immunohistochemical subgroups 
 CD5-positive DLBCL 
 Germinal centre B-cell-like (GCB) 
 Non-germinal centre B-cell-like (non-GCB) 
 
Diffuse large B-cell lymphoma subtypes 
T-cell/histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the CNS 
Primary cutaneous DLBCL, leg type 
EBV-positive DLBCL of the elderly 
 
Other lymphomas of large B-cells 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 




Large B-cell lymphoma arising in HHV-8-associated multicentric Castelman disease 
Primary effusion lymphoma 
 
Borderline cases 
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt          
lymphoma 












The DLBCL cells frequently express the pan-B-cell markers CD19, CD20, CD22 and 
CD79a, and in 50-75% of cases also immunoglobulin (Loddenkemper et al. 2004) (Table 
2, Figure 2B). In about 10% of the de novo DLBCL, CD5 is expressed on neoplastic cells 
(Tagawa et al. 2005), although it is distinguished from mantle cell lymphomas by the lack 
of cyclin D1 expression. The frequency of CD10, BCL6 and IRF4/MUM1 expression 
varies. The GC markers CD10 and BCL6 are found in 30-60% and 60-90% of cases, 
respectively. The IRF4/MUM1 marker indicative for the post-GCB phenotype is 
expressed in 35-65% of cases (Colomo et al. 2003, Berglund et al. 2005, Muris et al. 2006, 
Amen et al. 2007). A high FOXP1 expression is also demonstrated in post-GCB DLBCLs 
(Barrans et al. 2004). In contrast to normal B-cells, co-expression of both GCB and post-
GCB markers may be observed in lymphoid cells (Falini et al. 2000). Ki-67 expression 
reflecting the proliferation grade of the DLBCL cells is usually high, in some cases up to 
90% (Miller et al. 1994). 
 
DLBCLs have heterogeneous chromosomal abnormalities (Table 2) (Offit et al. 1995, 
Muramatsu et al. 1997, Chaganti et al. 1998, Kramer et al. 1998). The most common are 
t(14;18)(q32;q21), involving the BCL2 gene, and rearrangement of BCL6 at region 3q27, 
each manifesting in about one-third of DLBCLs. The MYC oncogene present on region 
8q24 is rearranged in about 10% of cases. In addition, rearrangements of immunoglobulin 
chains and somatic hypermutations targeting multiple genetic loci may contribute to the 



























5.2 Prognostic clinical factors in DLBCL 
DLBCL is characterized as a rapidly proliferating lymphoma usually accompanied by 
lymphadenopathy. However, extranodal presentation may confuse the clinical picture.  
 
The Ann Arbor staging, based on the spreading of the disease to adjacent lymph nodes, 
was originally developed for patients with Hodgkin’s lymphoma (Lister et al. 1989). The 
classification, currently also applied to NHLs, is less accurate in DLBCL due to the early 
dissemination and involvement of extranodal sites. However, to manage the disease, 
evaluation of the extension of the lymphoma is essential. In approximately 50% of 
patients, the lymphoma is localized to a single lymph node region (stage I) or to multiple 
lymph node regions restricted to one side of the diaphragm (stage II). Patients with a more 
widespread stage III disease have affected lymph node regions on both sides of the 
diaphragm. In cases of involvement of one or more extranodal sites, the lymphoma is 
considered to be stage IV. Up to 40% of DLBCL patients will have at least involvement of 
one extranodal site, and the stage is then designated with an E (Harris et al. 1994). Any 
site may be involved, among others, bone, bone marrow, testis, nasopharynx and 
gastrointestinal tract. About one-third of patients will present with B-symptoms, including 
weight loss, fever or night sweats, at the time of diagnosis. If the patient has B-symptoms, 
the stage of the disease is indicated with a B, otherwise with an A. Due to the rapid 
progression of the lymphoma, bulk tumours with a diameter over 10 cm are demonstrated 
in about 30% of patients, and the stage is then designated with an X. Involvement of 
extranodal sites and several affected lymph node regions have been observed to be 
negative predictors of survival (Hoskins et al. 1991, Nicolaides et al. 1998, Yang et al. 
2009). Moreover, a large tumour mass is associated with poor prognosis (Pfreundschuh et 
al. 2008a).  
 
The increased use of positron emission tomography with fluorine-18 fluorodeoxyglocose 
(18FFDG-PET) in clinical practice and particularly in staging and response assessment of 
lymphomas has led to the revision of the response criteria of lymphomas (Cheson et al. 
2007). A 18FFDG-PET-positive lymphoma delineates the extent of the disease, whereas a 
negative 18FFDG-PET defines the metabolic remission of the lymphoma. In addition to the 
role in response evaluation, 18FFDG-PET has a prognostic value in DLBCL patients. A 
positive 18FFDG-PET after chemotherapy treatment or before HDT and ASCT was 
reported to predict a short progression-free survival (PFS) (Spaepen et al. 2001 & 2003). 
However, the role of interim 18FFDG-PET during treatment remains unclear (reviewed in 






5.2.1 International Prognostic Index 
To develop a model for outcome prediction, the International Non-Hodgkin Lymphoma 
Prognostic Factor Project (1993) retrospectively analysed clinical data on about 3000 
aggressive lymphoma patients treated with chemotherapy and defined the following five 
clinical factors: age over 60 years, stage III or IV disease, elevated serum LDH level, more 
than one involved extranodal site and an Eastern Cooperative Oncology Group (ECOG) 
performance status of 2 or 3. The division of patients according to IPI scoring identified 
risk groups with different survival rates. The 5-year overall survival (OS) observed for the 
low-risk (none or one factor), low intermediate-risk (two factors), high intermediated-risk 
(three factors) and high-risk (four or five factors) groups was 73%, 51%, 43% and 26%, 
respectively (Table 3). The prognostic value of IPI has been confirmed in DLBCL patients 
(Nicolaides et al. 1998, Wilder et al. 2002). Currently, in clinical practice, IPI risk 
stratification is the only available tool to estimate risk of relapse and death at diagnosis.  
 
As comorbidity of elderly patients may determine the choice of treatment, an age-adjusted 
IPI (aa-IPI) was also validated in the IPI Project (International Non-Hodgkin´s Lymphoma 
Prognostic Factor Project 1993). The aa-IPI risk stratification is based on stage, serum 
LDH and performance status. Patients with an aa-IPI score of 0 have a favourable 
outcome, whereas patients with a score of 1, and 2 or 3 have an intermediate and poor 
prognosis, respectively.  
 
IPI risk stratification was incorporated into clinical practice before immunochemotherapy 
became a treatment of choice in DLBCL. Sehn et al. (2007) reported a retrospective 
analysis of the prognostic value of IPI in the post-rituximab era of lymphoma therapies. In 
a cohort of 365 R-CHOP-treated DLBCL patients, the predictive value of IPI remained, 
but instead of the originally described four groups, the authors revised the IPI 
classification (R-IPI) by redistributing the patients into three separate groups of very good 
(score 0), good (score 1-2) or poor (score 3-5) outcome. Accordingly, a significant 
difference in survival between the groups was observed, with a four-year PFS of 53%, 
80% and 94%, respectively. The corresponding OS rates were 55%, 79%, and 94% (Table 
3). 
 
In case of relapsed DLBCLs, the secondary IPI and aa-IPI determined before the second-
line HDT combined with ASCT can identify patients with favourable or unfavourable 






5.3 Treatment of de novo DLBCL 
A considerable proportion of DLBCL may be cured, with the outcome depending on 
patient and tumour characteristics. When antracyclin-containing multidrug chemotherapy 
regimens were standard therapy from the 1970s to the 1990s, approximately half of the 
patients were cured. Since studies comparing different multi-agent chemotherapies could 
not demonstrate difference in outcomes between treatments, CHOP was accepted as a 
first-line regimen for DLBCL patients (Gordon et al. 1992, Cooper et al. 1994, Fisher et 
al. 1994). Earlier, radiotherapy alone was considered a treatment option, but currently it is 
administered after chemotherapy to patients with limited or bulky diseases.     
 
Since 2000, treatment results of DLBCL have improved significantly with increased 
frequency or intensity of the chemotherapy regimen. Pfreundschuh et al. (2004a & 2004b) 
studied the impact of dose-intensification on the outcome of both young (<60 years) and 
elderly DLBCL patients. They compared CHOP administered every two or three weeks, 
with or without etoposide (CHOP-14, CHOP-21, CHOEP-14 and CHOEP-21). In the 
group of young patients, an improved OS was observed for those receiving the regimen in 
two-week cycles compared with three-week cycles. The addition of etoposide significantly 
enhanced the event-free survival (EFS); however, no improvement in OS was detected 
(Pfreundschuh et al. 2004b). In the trial with elderly patients, the CHOP-14 arm had 
superior survival to the CHOP-21 arm, but the outcome was not further improved by the 
addition of etoposide, due to increased toxicity (Pfreundschuh et al. 2004a). 
Table 3. Predicted survival (%) of DLBCL patients according to IPI and R-IPI risk 
stratifications.  
    No. of patients (%) 
5-yr OS after 
CT1 (%) 
 
4-yr OS after 
ICT2 (%) 
4-yr PFS after 
ICT2 (%) 
Standard IPI risk       
low (0-1)                  
low-intermediate (2) 
high-intermediate (3) 













                                               
82                               
81                             
49                         
59 
                                
 
85         
80         
57        
51 
R-IPI prognosis       
very good (0)            











                                 
94                         
79                          
55 
                       
94                   
80                   
53 
NA, not available.                                                                                                                               







The improved treatment achieved in DLBCL during recent years is primarily the result of 
combining rituximab with chemotherapy. Rituximab is a recombinant humanized 
monoclonal antibody targeting the CD20 antigen. CD20 is not present in B-lymphoid stem 
cells, but is expressed through the maturation of B-cells from pre-B-stage to antibody-
secreting plasma cells. The majority (90%) of B-cell neoplasms express CD20. The 
mechanisms of action of rituximab in vitro include antibody-dependent cell-mediated 
cytotoxicity, complement-mediated lysis and direct induction of apoptosis (reviewed in 
Smith 2003).  
 
Initially, rituximab was incorporated in the treatment of indolent lymphomas. However, 
subsequent to positive results in phase II studies (Coiffier et al. 1998, Vose et al. 2001), 
several large randomized phase III studies (Table 4) comparing immunochemotherapy 
with chemotherapy in different subsets of DLBCL patients have been conducted and were 
further evaluated in a recent meta-analysis (Gao et al. 2009). The positive results in the 
phase 3 studies place immunochemotherapy into a new standard of care. 
 
The French Lymphoma Group GELA was the first to report results of a significant 
advantage of R-CHOP treatment relative to CHOP for elderly untreated DLBCL patients 
(Coiffier et al. 2002). The two-year OS observed for patients treated with eight cycles of 
R-CHOP-21 was 70%, in comparison with 57% for patients receiving CHOP-21 eight 
times. The corresponding five-year OS rates were 58% and 45% (Feugier et al. 2005).  
Similarly, the German Lymphoma Group analysed the benefit of rituximab for young (<60 
years) DLBCL patients in the MInT trial (Pfreundschuh et al. 2006). The outcome of the 
patients with favourable or intermediate-risk disease (aa-IPI 0-1) after R-CHOP-like 
treatment was superior to that of similar regimens without rituximab. The estimated three-
year EFS was 79% after immunochemotherapy compared with 59% after chemotherapy, 
and the difference in OS remained significant. The ECOG study group randomized elderly 
patients to receive either CHOP or R-CHOP, followed by rituximab maintenance or no 
maintenance for patients responding to the induction treatment (Habermann et al. 2006). A 
benefit of rituximab on PFS was demonstrated, when it was administered either as a part 
of the induction or maintenance treatment, but no advantage was reported if rituximab was 
used in both settings. For OS, no difference was observed between the arms, probably 









Table 4. Major randomized studies comparing chemotherapy with rituximab combined with 
chemotherapy in de novo DLBCL patients.  
DLBCL study Patient 
characteristics 




399, elderly >60 yrs 
N=202 
N=197 
5-yr EFS p=0.00002 
47% 
29% 






824, young <60 yrs 
N=413 
N=410 
3-yr EFS, p<0.0001 
79% 
59% 



















3-yr FFS, p=0.003 
52% 
39% 
2-yr FFS, p<0.001 
     77% 
     79% 
     74% 
     45% 




























mR, maintenance rituximab, NA, not available. 
1Feugier et al. (2005), 2Pfreundschuh et al. (2006), 3Habermann et al. (2006),                





Furthermore, intensification of immunochemotherapy was studied in a randomized 
RICOVER-60 trial, where six or eight cycles of bi-weekly CHOP-14 with or without 
rituximab were administered to elderly patients with aggressive B-cell lymphoma 
(Pfreundschuh et al. 2008b). The results showed that both six and eight cycles of R-
CHOP-14 significantly improved survival over CHOP. In addition, the outcome of the 
patients was better after six cycles than after eight cycles of R-CHOP14, probably because 






based retrospective study, the survival of DLBCL patients in the pre- and post-rituximab 
eras was analysed, and addition of rituximab to chemotherapy was reported to 
significantly improve survival (Sehn et al. 2005). Similarly, in our experience, the 
outcome of DLBCL patients at the Department of Oncology in Helsinki University 
Hospital has improved with immunochemotherapy, as the 3.5-year OS was 72% after R-
CHOP and 49% after CHOP treatment (reviewed in Leppä et al. 2009).  
5.3.2 High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) 
The aim of HDT is to improve survival by intensifying the cytotoxic effect of the 
treatment. As a supportive action, ASCT is performed to reduce potentially fatal side-
effects caused by depletion of bone marrow stem cells following treatment. BEAC or 
BEAM are the most widely used chemotherapy regimens in lymphoma patients.   
 
Randomized trials have yielded conflicting results on the impact of upfront HDT and 
ASCT in aggressive NHL patients. According to a meta-analysis, low-risk patients have 
no evidence of improved survival after HDT compared with conventional chemotherapy, 
and data on the benefit of HDT and ASCT for high-risk patients are controversial (Strehl 
et al. 2003, Greb et al. 2007, reviewed in Greb et al. 2008). Previously, though, before 
rituximab was available, combined HDT and ASCT was considered a treatment option for 
young high-risk DLBCL patients in Finland, as less than half of the patients were cured 
with conventional chemotherapy (Shipp et al. 1999, Greb at al. 2007). In the 
immunochemotherapy era, the role of HDT and ASCT as a first-line therapy is unclear, 
since the treatment-related mortality is more extensive than with conventional 
chemotherapy.  
5.3.3 Treatment of relapsed DLBCL 
In young patients with an aggressive chemosensitive lymphoma relapse, the use of HDT 
and ASCT is an attempt to achieve a cure. The addition of rituximab to the induction 
chemotherapy in the salvage setting prior to HDT and ASCT decreases the risk for 
secondary relapse (Kewalramani et al. 2004, Vellenga et al. 2008). However, for those 
DLBCL patients who do not achieve complete remission or who suffer an early relapse 
after immunochemotherapy, the prognosis is predominantly poor (Martin et al. 2008) and 







5.4 Prognostic biomarkers in DLBCL 
5.4.1 Gene expression profiling  
Clinical and morphological heterogeneity of DLBCL suggests that biologically important 
subtypes, which may help us to tailor the therapy, ought to be defined. The development 
of DNA microarrays has provided an opportunity to identify gene expression signatures of 
the tumours that define both novel molecular entities and molecular predictors for 
survival. A DNA microarray consists of thousands of spots of previously identified genes. 
The array measures the differences in mRNA levels between the lymphoma samples and 
the results are usually presented in a heat map, where overexpressed or downregulated 
genes are shown in red and green, respectively. The profiling in DLBCL has identified 
several signatures that are both associated with unfavourable outcome after treatment and 
emphasize the similarities between tumour cells and normal B-lymphocytes (reviewed in 
Abramson & Shipp 2005). The comparison of studies identifying DLBCL gene signatures 
is somewhat difficult, as the identified genes are mainly non-overlapping, and 
methodological and material differences exist. Discrepancies may, for instance, derive 
from the measured genes, the microarray techniques (oligonucleotide or cDNA arrays), 
the computational approaches or the patient samples (frozen or paraffin-embedded 
tissues). In some cases, though, the constructed molecular predictor gene expression 
signatures have been studied in both preliminary and validation groups (Rosenwald et al. 
2002). Unfortunately, the challenging microarray technique and the lack of available 
frozen material diminish the value of the method in daily clinical practice.  
5.4.1.1 Cell of origin 
The early GEP studies have demonstrated that DLBCL can be divided into two molecular 
entities differing in gene expression profiles. The phenotypes share similarities to normal 
B-lymphocytes, but have shown different clinical outcomes (Alizadeh et al. 2000). The 
GCB subgroup, accounting for about 50% of cases, had the expression profile of normal 
GC B-cells. By contrast, the other activated B-cell-like (ABC) subgroup lacked the 
expression of GC genes and resembled activated B-cells. Initially, a type-3 group was also 
defined, comprising the unclassified cases. According to the GEP classification, the 
observed prognosis differed for the two major subtypes after antracyclin-based 
chemotherapy. GCB patients showed a more favourable outcome, with a five-year OS of 
76% compared with 16% for ABC patients. Distinction of the GCB and ABC signatures 






and were further confirmed in other retrospective series with chemotherapy-treated 
patients (Rosenwald et al. 2002, Shipp et al. 2002, Wright et al. 2003, Monti et al. 2005). 
One study observed no significant difference in outcome, although the phenotypes were 
apparent in the profiling (Poulsen et al. 2005).  
 
Molecular profiling can differentiate GCB and ABC DLBCLs according to intracellular 
pathway activities and oncogenic mechanisms (Rosenwald et al. 2002, Bea et al. 2005, 
Tagawa et al. 2005, Iqbal et al. 2006, Gleissner et al. 2008). The t(14;18)-deregulating 
BCL2 (45%) and the c-REL locus amplification on chromosome 2p (16%) occur 
predominantly, if not exclusively, in the GCB phenotype (Huang et al. 2002, Rosenwald et 
al. 2002). By contrast, the ABC DLBCLs are characterized by transcriptional 
overexpression of BCL2, chromosomal gains or amplifications in 3q and 18q21-q22 and 
losses in 6q21-q22 (Bea et al. 2005). Most importantly, a constitutive activation of the 
anti-apoptotic NF-κB signalling pathway appears in ABC but not in GCB DLBCLs (Davis 
et al. 2001, Rosenwald et al. 2002, Lam et al. 2005). Additionally, the GCB phenotype has 
ongoing Ig mutation, while none is observed in the ABC subgroup.  
 
Extranodal lymphomas also have variations in their gene expression signatures. The ABC 
subtype is commonly seen in primary CNS lymphomas (Camilleri-Broet et al. 2006, Lin et 
al. 2006) and testicular DLBCL (Booman et al. 2006). By contrast, gastric and intestinal 
DLBCL cases (Mitchell et al. 2008) are usually GCB subtypes. In addition to the GCB 
and ABC phenotypes, GEP has also identified the primary mediastinal large B-cell 
lymphoma (PMLBCL) as an uncommon subtype of DLBCL (Rosenwald et al. 2003, 
Savage et al. 2003). Currently, however, the PMLBCL is considered a separate entity in 
the WHO classification (Swerdlow et al. 2008). 
5.4.1.2 Additional gene expression-based models in the pre-rituximab era 
Several attempts have been made to identify gene expression profiles of DLBCL. The 
original cell-of-origin signature presented by Alizadeh et al. (2000) included 375 genes.  
However, the revised signature models identifying GCB and ABC subtypes involved a 
smaller amount of 100 (Rosenwald et al. 2002) or 27 genes (Wright et al. 2003). In the 
separate models, disagreement emerged for the unclassified type 3 tumours. Since DLBCL 
may include up to 40% type 3 tumours, a risk for misclassification is possible (Wright et 
al. 2003, reviewed in Abramson & Shipp 2005, Monti et al. 2005).  
 
Gene expression signatures other than the GCB and ABC phenotypes may also have an 






models based on the expression of 6-17 genes (Rosenwald et al. 2002, Shipp et al. 2002, 
Lossos et al. 2004). These are largely non-overlapping with the other signatures, with the 
exception of BCL6 and fibronectin genes. 
 
The Leukemia and Lymphoma Molecular Profiling Project defined on the basis of 
hierarchical clustering the “lymph node survival signature” in chemotherapy-treated 
DLBCL patients (Rosenwald et al. 2002). By selecting highly variable expression of 17 
genes, four characteristic groups could be identified: a GC B-cell, proliferating cells, 
reactive stromal and immune cells in the lymph node, MHC class II complex. Of these, 
the group with a proliferation signature was associated with poor outcome. By contrast, 
the outcome was favourable for the three remaining groups representing host responses. 
Another study used an oligonucleotide microarray technique and identified 13 different 
predictive genes that contributed to B-cell receptor signalling, regulation of cell cycle and 
apoptosis and serine/threonin phosphorylation in DLBCL patients with either cured or 
refractory disease (Shipp et al. 2002). Furthermore, Lossos et al. (2004) evaluated 
previously defined prognostic genes by applying a quantitative real-time polymerase chain 
reaction approach. A six-gene model for risk stratification was identified, which included 
the following genes as the strongest predictors: LMO2 and BCL6 involved in germinal 
centre formation, CCND2 in cell cycle progression, BCL2 in apoptosis, FN1 in 
cytoskeletal organization and CCL3 in inflammation.  The expression of BCL2, CCND2 
and CCL3 occurring in the ABC signature was correlated with a shorter survival. On the 
other hand, the GCB phenotype genes LMO2 and BCL6 and the lymph-node signature 
gene FN1 were correlated with prolonged survival. The impact on survival was 
independent of the IPI. The expression of MHC class II molecules was correlated with 
superior survival also independently of the GCB and ABC subtypes (Rosenwald et al. 
2002, Rimsza et al. 2004, Rimsza et al. 2006). 
 
The resistance of lymphoma cells to apoptosis may also be clarified with GEP, as subtypes 
with high expression of anti-apoptotic and cytotoxic effector genes have a poor outcome 
after chemotherapy (Muris et al. 2007). In addition, optional subtypes of DLBCL were 
identified by genes involved in the tumour microenvironment and host inflammatory 
response (Monti et al. 2005). These non-predictive subtypes expressed increased levels of 
genes associated with oxidative phosphorylation (BCL2 family), B-cell 






5.4.1.3 Stromal signature 
The cell-of-origin classification (Jais et al. 2008, Lenz et al. 2008), and the predictive six-
gene model (Malumbres et al. 2008) were reported to retain their predictive value also in 
DLBCL patients treated with immunochemotherapy. The Leukemia and Lymphoma 
Molecular Profiling Project reported a novel optimal survival model containing three 
signatures obtained by diversifying the “lymph node gene signature” (Lenz et al. 2008). In 
addition to the GCB signature, the model recognized a favourable stromal-1 signature and 
an unfavourable stromal-2 signature, both of which were characterized by non-malignant 
cells of the tissue. The stromal-1 group was representative of the extracellular matrix, 
collagen synthesis and connective-tissue growth factor. On the other hand, genes 
reflecting tumour angiogenesis and blood vessel density were represented by the stromal-2 
signature.  
 5.4.1.4 NF-κB signalling pathway in DLBCL 
The ABC DLBCL expresses several NF-κB target genes and has a constitutively active 
NF-κB pathway (Davis et al. 2001), which may support lymphocyte proliferation and 
survival. The NF-κB comprises a family of five members: RelA (p65), RelB, c-Rel, NF-
κB1 (p50/105) and NF-κB2 (p52/p100), that control genes associated with the activation 
and survival of B-cells (reviewed in Li & Verma 2002). The inducible transcription factor 
is bound as an inactive form to the inhibitor of NF-κB in the cytoplasm. The activation 
and phosphorylation of NF-κB occurs through the classical-canonical pathway by 
inflammatory stimuli or the alternative pathway triggered by tumour necrosis factor 
(TNF)-family members (reviewed in Bonizzi & Karin 2004). In the main classical 
pathway, the activation is controlled by the IκB kinases that phosphorylate the inhibitor 
proteins. This process leads to the release of the NF-κB members, which translocate to the 
nucleus and activate gene transcription. In DLBCL, the activation of NF-κB is mediated 
by the classical pathway and phosphorylation of p65, which correlates with favourable 
prognosis (Espinosa et al. 2008). In the ABC subtype, IκB kinases are constitutively active 
(Davis et al. 2001). The activation of NF-κB in DLBCL is, however, complex, as it is 






5.4.2 Immunohistochemical models as predictors of DLBCL 
Immunohistochemistry (IHC) is a part of the routine diagnostic procedure in most 
malignancies and of major importance in lymphomas. A predictive protein expression or 
algorithm based on a limited number of markers is an option to define molecular 
characteristics of DLBCL and outcome of patients.  
5.4.2.1 Cell of origin defined by the Hans algorithm 
The GEP-based identification of molecular subgroups has been translated to protein level 
by using IHC. The GCB and non-GCB subgroups were initially defined according to 
expression of CD10 and BCL6 (Barrans et al. 2002) or a combination of the previous 
markers together with MUM1/IRF4 and CD138 (Colomo et al. 2003). However, the 
results were inconsistent, and none of the IHC findings correlated with gene expression 
data. Subsequently, an algorithm defining the subgroups was developed.  
 
Hans et al. (2004) created tissue microarray (TMA) blocks from 142 cases that had also 
been categorized into GCB and ABC subgroups by GEP. The series included 75 GCB, 41 
ABC and 26 type 3 cases. The cases were subclassified to either GCB or non-GCB 
subgroups according to CD10, BCL6 and MUM1/IRF4 expression (Figure 3A). If the case 
was CD10-positive, it belonged to the GCB subgroup, while both CD10- and BCL6-
negative cases belonged to the non-GCB subgroup. If the case was CD10-negative and 
BCL6-positive, the MUM1/IRF4 expression defined the subgroup; MUM1/IRF4-negative 
cases were of GCB subtype and MUM/IRF4-positive cases of non-GCB subtype. 
According to the Hans algorithm, 42% of cases were considered to be GCB and 58% non-
GCB. The outcome for the TMA-based classification was observed to be similar to the 
cDNA-microarray based survival results, as the five-year OS for GCB patients was 76%, 
as opposed to 34% for patients with the non-GCB phenotype. By comparing the cDNA 
microarray and TMA classifications, 30 patients were considered to be misclassified. The 
reported sensitivity for TMA was 71% for the GCB and 88% for the non-GCB subgroups. 
In survival analysis, the outcome of the misclassified patients correlated best with the 
results of the TMA definition, as the TMA GCB or microarray ABC patients had a 
favourable survival. Similarly, the TMA non-GCB and microarray GCB patients had a 
poor outcome. The predictive value of the phenotype was independent of the IPI risk 
stratification. The authors concluded that the TMA classification might be more predictive 







Several studies have subsequently confirmed that the different prognostic subgroups of 
DLBCL can be identified by analysing a limited number of markers in the Hans algorithm 
(Berglund et al. 2005, Muris et al. 2006, Sjö et al. 2007, Lee et al. 2008, Seki et al. 2009). 
However, other studies have shown no difference in the outcome between GCB and non-
GCB patients (Colomo et al. 2003, De Paepe et al. 2005, Moskowitz et al. 2005, Amen et 
al. 2007, Dupuis et al. 2007, Peh et al. 2008, Ilic et al. 2009, Laszlo et al. 2009). 
Furthermore, separate immunophenotypes in the GCB subgroup have recently been 
reported to have different survivals. For instance, GCB cases that are CD10- and BCL6-
positive have a significantly shorter survival than CD10-negative, BCL6-positive or 
MUM1/IRF4-negative GCB patients (Anderson et al. 2009). All of these retrospective 
studies were performed on cohorts treated with CHOP-like chemotherapy. Thus, since the 
addition of rituximab to chemotherapy was accepted as standard treatment, it was essential 
to evaluate the prognostic relevance of the cell-of-origin classification in 
immunochemotherapy-treated DLBCL patients.    
5.4.2.2 Other algorithms defining cell of origin 
To further define the molecular features of DLBCL immunohistochemically, Muris et al. 
(2006) developed an algorithm that was based on not only expression of GCB and non-
GCB proteins but also anti-apoptotic BCL2 protein. Two different algorithms were 
presented in the series of chemotherapy-treated DLBCL patients. Firstly, the cases were 
defined as GCB or ABC-like phenotypes by omitting BCL6 from the algorithm and 
defining the subtypes according to the expression of CD10 and MUM1/IRF4. If the case 
was CD10-positive, or CD10- and MUM1/IRF4-negative, it was considered to represent 
the GCB phenotype. An ABC-like case had negative CD10 and positive MUM1/IRF4 
expression. The CD10- and MUM1/IRF4-based algorithm resulted in more ABC-like 
DLBCL cases than the Hans algorithm, but the predictive power on the outcome was 
similar for both algorithms. As BCL2 and CD10 were observed to be independent 
prognostic markers, the algorithm by Muris was further modified to optimize the 
stratification of the DLCBL into favourable (group 1) and unfavourable (group 2) 
subgroups (Figure 3B). Group 2 consisted of BCL2-positive, CD10-negative and 
MUM1/IRF4-positive cases, whereas the other phenotypes belonged to group 1. The 
favourable and unfavourable subgroups demonstrated a significant difference in survival. 
The prognostic impact of the algorithm was independent of the IPI risk stratification. Sjö 
et al. (2007) confirmed the prognostic value of the group 1 and 2 division, but reported 
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Figure 3. Molecular classifications of DLBCL by immunohistochemically defined algorithms. A) 
Algorithm by Hans et al. (2004). B) Algorithm by Muris et al. (2006). C) Algorithm by Amen et 






An additional attempt to improve the classification of DLBCL was based on the algorithm 
consisting of CD10, BCL6, cyclin D2 and BCL2 stainings (Amen et al. 2007). The cases 
positive for either CD10 or BCL6 represented the GCB phenotype, whereas CD10- and 
BCL6-negative cases belonged to the non-GCB phenotype. The GCB subgroup was 
further divided into cases with favourable (BCL2- and cyclin D2-negative expression) or 
unfavourable (either BCL2- or cyclin D2-positive) outcome (Figure 3C). The survival 
analysis demonstrated a significantly improved survival for the favourable GCB patients 
compared with the others group (non-GCB and poor GCB cases), whereas no prognostic 
impact was observed for the Hans algorithm. 
 
A novel immunohistochemically defined algorithm classifying DLBCL was validated in 
both chemotherapy- and immunochemotherapy-treated patients (Choi et al. 2009). By 
using the five markers GCET1, CD10, BCL6, MUM1/IRF4 and FOXP1, the cases were 
separated into GCB and ABC-like subgroups.  GCET1 is a marker limited to GC-   
derived lymphomas (Montes-Moreno et al. 2008). The GCB subgroup consisted              
of the following phenotypes: CGET+/MUM1/IRF4-, GCET1-/CD10+ and                                           
GCET1-/CD10-/BCL6+/ FOXP1-, whereas all others were considered to belong to the 
ABC subtype (Figure 3D). The reported three-year OS was 87% for GCB patients 
compared with 44% for patients with the ABC-like subtype. The new algorithm was 
reported to have a 93% concordance with the GEP classification.  
5.4.3 Individual prognostic markers 
The GEP has highlighted the heterogeneity of DLBCLs. Many new proteins have been 
identified as important prognostic factors in determining outcome of patients (Table 5). To 
date, the biological markers have improved our knowledge of the DLBCL biology, but 
much confusion remains (reviewed in Gascoyne 2004, Abramson & Shipp 2005 and 
Lossos & Morgensztern 2006).  
5.4.3.1 BCL6 
The transcriptional repressor, BCL6, mediates survival, proliferation and differentiation of 
B-cells by multifunctionally regulating germinal centre development and T-helper 2-
mediated antigen responses (Ye et al. 1997). The proto-oncogene BCL6 is involved in the 
chromosomal translocation affecting band 3q27 (Kerckaert et al. 1993, Chang et al. 1996, 
Seyfert et al. 1996). The BCL6 gene is normally strongly expressed in GC B- and T-






The prevalence of BCL6 translocations and rearrangements is reported to be higher in the 
ABC subgroup than in the GCB subgroup (Iqbal et al. 2007, Shustik et al. 2010). 
Generally, the presence of BCL6 gene rearrangements or mutations has no effect on the 
outcome of DLBCL patients (Bastard et al. 1994, Pescarmona et al. 1997, Kramer et al. 
1998, Capello et al. 2000, Jerkeman et al. 2002, Shustik et al. 2010). However, according 
to some reports, patients with BCL6 rearrangement have also had a superior (Offit et al. 
1994) or inferior (Tibiletti et al. 2009) survival in response to chemotherapy.  
 
High BCL6 mRNA level or BCL6 expression in lymphoma cells has been associated with 
a significantly improved survival (Lossos et al. 2001, Rosenwald et al. 2002, Hans et al. 
2004, Lossos et al. 2004, Iqbal et al. 2007, Sjö et al. 2007, Malumbres et al. 2008, Rimsza 
et al. 2008, Uccella et al. 2008, Seki et al. 2009), whereas another study reported that high 
BCL6 expression correlates with poor outcome (Peh et al. 2008). Furthermore, Winter et 
al. (2006) noted that the addition of R to CHOP interfered with the prognostic value of 
BCL6. A recent study, however, observed that BCL6 positivity was associated with 
superior survival after immunochemotherapy (Seki et al. 2009). 
5.4.3.2 MUM1/IRF4 
MUM1/IRF4 is a lymphocyte-specific member of the IRF family of transcription factors 
essential for the function of mature B-cells and cytotoxic T-lymphocytes (Mittrucker et al. 
1997). The MUM1/IRF4 protein is associated with the terminal phases of B-cell 
differentiation (Saito et al. 2007b). It also functions as a transcription repressor in early B-
cell development (Acquaviva et al. 2008). In addition to plasma cells, the protein is 
strongly expressed in activated T-cells and a subset of GC B-cells (Falini et al. 2000). 
 
As MUM1/IRF4 is associated with the ABC subtype, the predictive value of the protein 
has often been evaluated as part of the cell-of-origin algorithms. When the MUM1/IRF4 
protein was individually evaluated, positive expression was associated with unfavourable 
survival in DLBCL patients treated with chemotherapy, and in some cases with HDT 
supported by ASCT (Hans et al. 2004, Muris et al. 2006, van Imhoff et al. 2006, Amen et 
al. 2007, Veelken et al. 2007). By contrast, others have reported no prognostic value of 
MUM1/IRF4 positivity (Berglund et al. 2005, Sjö et al. 2007, Costa et al. 2008, Hallack 







The Forkhead box protein family consists of four transcription factors. The FOXP1 is 
expressed in different cell types, but its function is largely unknown. B-lymphocytes 
express FOXP1 at several stages of differentiation (Banham et al. 2001), to a lesser extent 
in resting B-cells than in activated B-cells (reviewed in Shaffer et al. 2002). The FOXP1 
gene has been reported to be upregulated in the unfavourable ABC subtype (reviewed in 
Shaffer et al. 2002, Brown et al. 2008, Lenz et al. 2008).  
 
FOXP1 expression was initially associated with poor prognosis (Barrans et al. 2004, 
Banham et al. 2005), although additional studies with chemotherapy-treated DLBCL 
patients reported no prognostic impact of FOXP1 on survival (Hans et al. 2004, Amen et 
al. 2007).  High FOXP1 expression has been observed in MALT lymphomas (Streubel et 
al. 2005) and may be related to transformation to DLBCL (Sagaert et al. 2006). 
5.4.3.4 Other biomarkers related to B-cell differentiation and signalling 
CD10 is a membrane surface metalloproteinase expressed in lymphoid cells in the follicle 
centres and is thought to be expressed during the first stages of immunoglobulin heavy 
chain rearrangements (McIntosh et al. 1999). Although CD10 is lost during the maturation 
of pro-B-cells to naïve B-cells, it reappears on the cell surface during antigen-dependent 
germinal centre maturation and may therefore serve as a GCB marker. The predictive 
value of CD10 for outcome is controversial. An improved prognosis has been reported in 
patients with high CD10 expression (Ohshima et al. 2001, Hans et al. 2004, Berglund et 
al. 2005, Muris et al. 2006, Sjö et al. 2007), whereas others have observed no difference in 
survival between CD10-positive and -negative DLBCL patients (Lossos et al. 2001, 
Colomo et al. 2003, Fabiani et al. 2004, Amen et al. 2007).  
 
The CD5 antigen is expressed in about 10% of DLBCL patients (Taniguchi et al. 1998), 
although it is mainly a marker for CLL and mantle-cell lymphomas. Relative to CD5-
negative DLBCL patients, cases with high CD5 expression have been reported to have a 
more widespread disease, involvement of extranodal sites and poorer prognosis after 
chemotherapy (Yamaguchi et al. 1999 & 2002, Linderoth et al. 2003, Suguro et al. 2006). 
However, the observation was not confirmed in another patient cohort (Katzenberger et al. 
2003). In the immunochemotherapy era, the results have also been controversial, as the 
prognostic impact of CD5 on survival was significant in patients treated with R-CHOP 
(Ennishi et al. 2008), while others reported that rituximab improved survival only in CD5-








The role of the specifically IL-4 induced human germinal centre-associated lymphoma 
(HGAL) gene is unknown (reviewed in Lossos & Levy 2003). As the HGAL protein is 
mainly expressed in the cytoplasm of GC lymphocytes and GCB-derived lymphomas, it 
may play a role in identifying the GCB subtype (Natkunam et al. 2005). A high HGAL 
mRNA level was associated with significantly longer survival than a low HGAL 
expression (Natkunam et al. 2005).  
Table 5. Prognostic molecular markers in DLCBL. 
Biomarker Proposed outcome Mechanism References 
BCL6 Favourable Transcription factor/repressor Hans et al. 2004, Lossos et al. 
2004, Iqbal et al. 2007 
MUM1/IRF4 Unfavourable Transcription factor Hans et al. 2004, Muris et al. 
2006, Amen et al. 2007 
FOXP1 Unfavourable Transcription factor Barrans et al. 2004, Banham et al. 
2005 
CD10 Favourable Neutral endopeptidase Hans et al. 2004, Berglund et al. 
2005,  Muris et al. 2006 
CD5 Unfavourable B-cell differentiation Yamaguchi et al. 2002, Linderoth 
et al. 2003, Suguro et al. 2006 
HGAL Favourable GC phenotype Natkunam et al. 2005 
PKC-β Unfavourable B-cell signaling Shipp et al. 2002, Hans et al. 
2005, Chaiwatanatorn et al. 2009 
LMO2 Favourable Transcription factor Lossos et al. 2004, Natkunam et 
al. 2008 
BCL2 Unfavourable Anti-apoptosis Lossos et al. 2004, Berglund et al. 
2005, Amen et al. 2007 
p53 mutation Unfavourable Cell cycle regulation Piris et al. 1994, Ichikawa et al. 
1997, Young et al. 2007 
Cyclin D2  Unfavourable Cell cycle regulation Hans et al. 2004 & 2005, Amen et 
al. 2007 
Mast cells Favourable Microenvironment/host response  Hedström et al. 2007 
FOXP3 Favourable Microenvironment/host response Le Na-Ri et al. 2008 
VEGF Unfavourable Regulator of angiogenesis Ganjoo et al. 2008, Gratzinger et 






The protein kinase Cβ is a member of the PKC family (α, βI, βII and γ), which plays a role 
in the activation and survival of B-cells, principally through the activation of the NF-κB 
pathway (Saijo et al. 2002). PKCβII protein levels have been reported to be higher in non-
GCB tumour cells than in GCB cells (Fridberg et al. 2007). According to gene expression 
studies, the PKCβ had prognostic value (Shipp et al. 2002). Likewise, the expression of 
PKCβ (Hans et al. 2005, Li et al. 2007) and PKCβII (Espinosa et al. 2006, Schaffel et al. 
2007) proteins is associated with poor outcome in chemotherapy-treated DLBCL patients. 
Moreover, high expression of PKCβII is correlated with adverse outcome after 
immunochemotherapy (Chaiwatanatorn et al. 2009, Riihijärvi et al. 2010).  
 
The LMO2 is a transcription factor included in the predictive six-gene model (Lossos et al. 
2004, Malumbres et al. 2008). The LMO2 protein is expressed in normal GC B-cells and 
partially in GCB-derived lymphomas (Natkunam et al. 2007, Copie-Bergman et al. 2009). 
LMO2 protein expression has been shown to have prognostic value, as a high level of 
LMO2 correlates with favourable survival in both chemotherapy- and 
immunochemotherapy-treated DLBCL patients (Natkunam et al. 2008). Recently, though, 
the expression of LMO2 protein was not associated with outcome in 
immunochemotherapy-treated patients (Copie-Bergman et al. 2009). 
 
Additionally, in DLBCL, improved survival has been linked to expression of CD19 
(Kimura et al. 2007), CD21 (Otsuka et al. 2004, Miyazaki et al. 2008), CD40 (Linderoth et 
al. 2003 & 2007b) and CD23 (Linderoth et al. 2003). The outcome was poor in DLBCL 
patients with positive CD43 (Mitrovic et al. 2009) and CD138 (Oh & Park 2006) 
expression. Reduced CD20 expression was also associated with inferior outcome (Johnson 
et al. 2009). The immunoreactivity of CD44 was associated with favourable survival 
(Drillenburg et al. 1999, Tzankov et al. 2003) and ICAM-1 with unfavourable outcome 
(Terol et al. 1998).  
5.4.3.5 BCL2 and markers related to apoptosis 
The family of BCL2 proteins contains both anti-apoptotic and pro-apoptotic members. 
BCL2 is a proto-oncogene promoting B-cell survival by inhibiting apoptosis. BCL2 
overexpression is observed in about 50% of DLBCLs. Of these, only 15% have the 
t(14;18), indicating that other mechanisms regulate the expression (Gascoyne et al. 1997). 
The BCL2 is deregulated in all molecular subtypes (Alizadeh et al. 2000). In the GCB 
subtype, BCL2 expression is associated with t(14;18), while in the ABC subtype higher 
BCL2 levels are observed as a consequence of amplification of the BCL2 gene or NF-κB 






the GCB lymphomas show high expression levels of pro-apoptotic proteins Bax, Bak and 
Bid, and low expression of the anti-apoptotic BCL-xL protein (Bai et al. 2004). 
 
The anti-apoptotic role of BCL2 (Hockenbery et al. 1990, Monni et al. 1997, Kramer et al. 
1998) suggests an advantage for the survival of lymphoma cells. However, the prognostic 
value of BCL2 expression remains to be clarified. Several studies in chemotherapy-treated 
DLBCL patients have shown an adverse impact of BCL2 expression on survival (Hermine 
et al. 1996, Gascoyne et al. 1997, Barrans et al. 2002, Colomo et al. 2003, Lossos et al. 
2004, Berglund et al. 2005, Amen et al. 2007, Veelken et al. 2007,  Rimsza et al. 2008, 
Seki et al. 2009), whereas others have observed no predictive value for BCL2 (Piris et al. 
1994, Wilson et al. 2007, Winter et al. 2008). Furthermore, expression of the BCL2 
protein and BCL2 gene aberrations were reported to predict poor outcome only in the 
ABC subgroup (Iqbal et al. 2006, Obermann et al. 2009). 
 
Caspases are involved in the apotosis signalling pathway, and survivin is an inhibitor 
protein of apoptosis. Expression of caspase 3 and 8 was observed to correlate with 
favourable outcome, while caspase 9 was associated with shorter survival of DLBCL 
patients (Muris et al. 2005). In addition, survivin expression was related to poor outcome 
(Adida et al. 2000, Watanuki-Miyauchi et al. 2005).  
5.4.3.6 p53 and other cell cycle regulators 
Cell cycle regulators, like p53, are important in regulating the balance between cell 
proliferation and death. In normal conditions, the p53 protein arrests the cell cycle in 
response to DNA damage. Mutations in the p53 gene disturb its regulatory function and 
lead to uncontrolled cell growth (reviewed in Levine et al. 2006). The incidence of p53 
mutations is lower in haematological malignancies than in other solid tumours (reviewed 
in Preudhomme & Fenaux 1997 and Peller & Rotter 2003). Several studies have 
demonstrated that p53 mutations are associated with poor prognosis (Ichikawa et al. 1997, 
Moller et al. 1999, Leroy et al. 2002, Kerbauy et al. 2004, Young et al. 2007 & 2008), 
especially in the GCB subset of patients (Young et al. 2008, Zainuddin et al. 2009). In a 
few studies, however, no association between p53 mutations and outcome was found 
(Osada et al. 1999, Barrans et al. 2002). Results of the impact of p53 protein expression 
are also inconsistent, as high expression was either associated with shorter survival (Piris 
et al. 1994, Stewart et al. 2009) or had no prognostic value (Kramer et al. 1996, Jerkeman 
et al. 2004). The p53+/p16-/p14- and p53+/p21- phenotypes were more frequently 
observed in the GCB subtype (Paik et al. 2005, Visco et al. 2006), where they were 






was demonstrated to predict both a poor (Fukushima et al. 2006) and a good (Hallack 
Neto et al. 2009b) prognosis, as well as to correlate with high proliferation of DLBCL 
cells (Hedvat et al. 2005).  
 
Cyclins are cell cycle-regulating proteins, often deregulated in malignant cells. In 
DLBCL, expression of cyclin B1 (Obermann et al. 2005), cyclin D2 (Hans et al. 2004 & 
2005, Amen et al. 2007), cyclin D3 (Filipits et al. 2002) and cyclin E (Tzankov et al. 
2006) has been associated with poor prognosis.  
 
The nuclear antigen Ki-67 is present in all cycling cells, and the proportion of Ki-67 in 
positive cells reflects the proliferation rate of the tumour. In DLBCL, the reported 
prognostic value of Ki-67 is controversial. High Ki-67 expression was demonstrated to be 
associated with poor prognosis (Grogan et al. 1988, Miller et al. 1994, Sanchez et al. 1998, 
Broyde et al. 2009), although other studies have reported a favourable outcome for 
patients with positive Ki-67 expression (Wilson et al. 1997, Jerkeman et al. 2004, 
Hasselblom et al. 2008b). 
5.4.3.7 Microenvironment 
The tumour microenvironment plays a crucial role in cancer development, and, for 
instance, in FL, the immune cells may be more important than tumour cells in predicting 
survival (Dave et al. 2004, Farinha et al. 2005, Taskinen et al. 2007). In DLBCL, GEP 
identified a subset of DLBCLs characterized by host inflammatory response (Monti et al. 
2005). Genes associated with the tumour microenvironment have been described to be 
overexpressed in DLBCL patients with continuous remission (Linderoth et al. 2008). At 
the tissue level, large amounts of lymphoma-infiltrating T-lymphocytes (Ansell et al. 
2001) and mast cells (Hedström et al. 2007) were associated with superior outcome in 
DLBCL patients. However, unlike in FL, the amount of CD68-positive macrophages in 
the tumour was not observed to be associated with outcome (Hasselblom et al. 2008a). 
Interestingly, high tumour-associated macrophage content has been noted in DLBCL 
patients who are cured after chemotherapy (Linderoth et al. 2008). 
 
The transcription factor FOXP3 has been identified as an important regulator of 
CD4+CD25+ regulatory T-cells and is accepted as their marker (Hori et al. 2003, 
reviewed in Li et al. 2006). Regulatory T-cells play a role in immunological tolerance and 
may contribute to tumour progression (reviewed in Beyer & Schultze 2006). An increased 
number of immunohistochemically defined FOXP3 positive regulatory T-cells was shown 






2008), although high expression of these cells was also associated with a poor prognosis in 
high-risk patients (Saez et al. 2009). 
 
Angiogenesis is essential in tumourgenesis and tumour growth (reviewed in Hanahan & 
Folkman 1996). Aggressive lymphomas have an intensified stromal haemangiogenesis 
(Ruan et al. 2006), and therefore, pro- and anti-angiogenic growth factors may serve as 
predictive factors. High expression of VEGF and VEGF receptors correlated with an 
adverse outcome in DLBCL patients treated with chemotherapy (Ganjoo et al. 2008, 
Gratzinger et al. 2008, Jørgensen et al. 2009) and immunochemotherapy (Gratzinger et al. 
2010). 
5.4.3.8 Soluble serum markers  
The more studied prognostic markers are the ones evaluated in lymphoma cells and the 
microenvironment of tissue samples. However, predictive soluble serum markers have 
also been found in both chemotherapy- and immunochemotherapy-treated DLBCL 
patients. Examples including elevated serum levels of beta-2 microglobulin, LDH (Suki et 
al. 1995), adhesion molecule CD44 (Ristamaki et al. 1997), ICAM-1 (Terol et al. 2003), 
IL-2 receptor (Ennishi et al. 2009, Morito et al. 2009), the TNF-receptor family member 
Fas (Hara et al. 2009) and L-kynurenine (Yoshikawa el al. 2009) have predicted poor 
outcome. Soluble markers evaluated in serum samples have practical applicability; 
however, these markers are not lymphoma-specific and can therefore also reflect other 






6. AIMS OF THE STUDY  
 
The major aim of this thesis was to determine the role of immunohistochemically defined 
molecular predictors related to cell of origin in DLBCL patients treated with 
immunochemotherapy.  
 
Specific aims were as follows: 
 
1) To determine the prognostic impact of GCB and non-GCB phenotypes according to the 
Hans algorithm in DLBCL patients treated with a combination of rituximab and 
chemotherapy (I). 
 
2) To investigate the predictive value of the cell-of-origin classification in DLBCL 
patients treated with HDT and ASCT (II). 
 
3) To define the prognostic impact of the ABC-associated markers BCL2 and FOXP1 in 
immunochemotherapy-treated DLBLCs (III). 
 
4) To develop a novel algorithm and test its applicability in predicting outcome in DLBCL 

















7. PATIENTS AND METHODS 
7.1 Patients and treatments 
Patients were selected on the basis of availability of clinical information and histological 
material. In Studies I-IV, the series consisted partly of the same patient cases. All patient 
data were collected retrospectively. The following clinical characteristics of each patient 
were obtained from medical records: age at diagnosis, sex, performance status, Ann Arbor 
stage at presentation, extranodal involvement, serum LDH level and therapy regimen. IPI, 
aa-IPI and R-IPI were determined. For survival analysis, the dates for diagnosis, 
treatment, relapse, last follow-up, and death of any cause were recorded. The endpoints 
were defined according to the Cheson criteria (Cheson et al. 1999). None of the patients 
were immunodeficient. All cases were diagnosed by a haematopathologist as CD20-
positive DLBCLs, according to the WHO classification (Jaffe et al. 2001). The protocols 
and samplings were approved by the local Institutional Review Boards, the Ethics 
Committee at the Department of Surgery at the Hospital District of Helsinki and Uusimaa 
and the Finnish National Authority for Medicolegal Affairs.  
 
Study I 
The series consisted of 194 de novo DLBCL patients diagnosed and treated at University 
Hospitals in Helsinki, Finland, and Uppsala, Sweden. The patients were treated between 
1994 and 2004, a time period before rituximab was adapted to standard treatment and a 
period of immunochemotherapy treatment. Ninety patients received 
immunochemotherapy, i.e. rituximab combined with a CHOP-like regimen, whereas 104 
chemotherapy-treated patients served as a control group. CHOP was administered to about 
58% of the cases in both treatment arms, whereas the remaining regimens consisted of 
CHOEP, VACOP, MACOP-B, EPOCH and CNOP. The study included 107 males and 87 
females. The median age of the patients in the rituximab group was 60.9 (range 23-82) 
years and in the control group 62.0 (range 25-83) years. The median follow-up for 
immunochemotherapy-treated patients was 27 months and for chemotherapy-treated 
patients 52 months. 
 
Study II 
From 1994 to 2002, we collected data on 29 young high-risk DLBCL patients receiving 
first-line treatment with HDT and ASCT at the Departments of Oncology and 
Haematology in Helsinki and Kuopio, Finland. The control group consisted of 34 young 






patients were aged under 64 years, with an Ann Arbor stage III or IV disease and an aa-
IPI≥1. The median follow-up for the ASCT group was 8 years and for the control group 4 
years. As an induction treatment, 5-7 cycles of chemotherapy was typically administered. 
The chemotherapy included CHOP and CHOP-like regimens, and as a consolidation 
treatment BEAC or BEAM was administered. None of the patients received rituximab. 
 
Study III 
This cohort consisted of 117 DLBCL patients diagnosed and treated with 
immunochemotherapy during 2002-2006 at the Departments of Oncology in Helsinki, 
Finland, and in Uppsala and Lund, Sweden. Of the patients, 76% were treated with an R-
CHOP regimen and the rest received R-CHOEP. The median age was 63.3 (range 18-84) 
years, with 61% of the patients being over 60 years. The median follow-up was 29 
months. At the time of data analysis, 28 patients had relapsed and 19 subsequently died. 
 
Study IV  
In this series, we collected 88 uniformly immunochemotherapy-treated de novo DLBCL 
patients. The only accepted therapy regimen was R-CHOP. Patients were diagnosed and 
treated at the Departments of Oncology in Helsinki, Finland, and Lund, Sweden, during 
2002-2006. The median follow-up at the time of data analysis was 37 months. The median 
age of the 42 male and 46 female patients was 66.6 (range 18-84) years.  
7.2 Immunohistochemistry 
Diagnostic paraffin blocks were collected from the patients from Studies I-IV at the time 
of diagnosis. Only whole-tissue sections were used in the analysis. Paraffin sections of 4-
µm thickness were mounted on Vectabond-coated slides and kept at +37°C for 24 h and 
then stored at 4°C. 
 
CD10, BCL6, MUM1/IRF4 and BCL2 (I-IV) 
The immunohistochemical stainings were performed according to the following 
procedure. The sections were kept at 56°C for 30 min. Deparaffinization was carried out 
by using the sections in xylene, which were rehydrated through a series from graded 
alcohol to water. For antigen retrieval, sections were treated in a pressure cooker for 2 min 
in 0.01M sodium citrate buffer (pH 6.0), washed with phosphate-buffered saline (PBS) 
and incubated in hydrogen peroxidase. After rewashing with PBS, Vectastain ABC mouse 
kit reagents (Vector Laboratories, USA) were used according to the manufacturer’s 






BCL2 were diluted 1:200, 1:20, 1:100 and 1:100, respectively, in 0.3% bovine serum 
albumin (BSA) PBS. After antibody administration at room temperature (RT), sections 
were incubated overnight at 4°C. During the following day, IHC was completed using the 
Vectastain ABC kit. The immunoreactions were visualized with 3-amino-9-ethylcarbazole 
(AEC) or 3,3´-diaminobenzidine (DAB) at RT for 10 min. After washing the slides with 
PBS and distilled water, the sections were counterstained with Mayer haematoxylin and 
mounted for microscopy examination.  
 
FOXP1 (III, IV) 
In the immunohistochemical staining procedure of FOXP1, deparaffinization and 
rehydration were performed as described above. The sections were then cooked in a 
microwave oven in trishydroxymethylaminomethane/ethylenediaminetetraacetic acid 
(Tris/EDTA, pH 9.0) for 3 x 4 min. For immunohistochemical detection, the Dako 
Cytomation Envision System-HRP DAB kit (Dako Cytomation, Denmark) was used 
according to the manufacturer’s instructions. The FOXP1 (JC12) mouse antibody was 
diluted 1:80 in PBS and 10% human serum and incubated on the slides for 30 min at RT. 
After completing the Envision Kit procedure, Mayer haematoxylin was applied for 
counterstaining, followed by mounting.  
 
A histological section of normal lymph node was used as a positive control for all specific 





Table 6. Antibodies used in immunohistochemical stainings. 
Antigen Antibody Dilution Manufacturer 
CD10 monoclonal mouse 1:200 Novocastra Laboratories, United Kingdom 
BCL6 monoclonal mouse 1:20 Dako Cytomation, Denmark 
MUM1/IRF4 monoclonal mouse 1:100 Dako Cytomation, Denmark 
BCL2 monoclonal mouse 1:100 Dako Cytomation, Denmark 






7.3 Evaluation of immunoreactivity 
The evaluation of immunoreactivity was supervised by an experienced haematopathologist 
(M-LK-L, Helsinki). The sections were analysed by one or two independent investigators. 
The immunostainings were evaluated with a Leica DM LB bright-field microscope (Leica 
Microsystems GmbH) at 40x magnification. Only nuclear staining for BCL6, 
MUM1/IRF4 and FOXP1, nuclear and cytoplasma staining for BCL2 and membrane 
staining for CD10 were evaluated in lymphoma cells (Figure 4). No follicular areas were 
evaluated. According to previous studies (Hans et al. 2004, Berglund et al. 2005), the 
sections were scored positive for CD10, BCL6 and MUM1/IRF4 if 30%, and for BCL2 if 
50% or more of lymphoma cells were positive. The cut-off for FOXP1 expression was 
deemed positive if 30% (Hans et al. 2004, Banham et al. 2005, Amen et al. 2007), and 
strongly positive if 100% of lymphoma cells showed positive immunoreactivity (Barrans 
et al. 2004). In Studies III and IV, the strongly positive 100% cut-off level was used for 
FOXP1 staining, as the distribution of the positive and negative cases was the most 
comparable with the previous study (Barrans et al. 2004).  
 
 
Figure 4. Positive expression in immunohistochemical stainings for A) CD10, B) BCL6, C) 







7.4 Immunohistochemical classifications of cell of origin 
Three different classifications identifying the cell of origin were used: the Hans algorithm 
(Studies I-IV), the Muris algorithm (Study IV) and the modified ABC-like algorithm 
(Study IV). 
 
According to the Hans algorithm (Figure 3A), cases were assigned to the GCB phenotype 
if CD10 or both CD10 and BCL6 were positive. If both CD10 and BCL6 were negative, 
the case was assigned to the non-GCB subgroup. In cases where CD10 was negative and 
BCL6 positive, MUM1/IRF4 expression determined the subgroup; MUM1/IRF4-positive 
cases were considered to belong to the non-GCB subgroup and MUM1/IRF4-negative 
cases to the GCB subgroup.    
 
According to the Muris classification in Figure 3B, the cases were assigned to group 1 if 
BCL2 was negative or if both BCL2 and CD10 were positive. In cases where BCL2 was 
positive and CD10 negative, MUM1/IRF4 determined the subgroup; MUM1/IRF4-
negative cases were considered to belong to group 1 and MUM1/IRF4-positive cases to 
group 2.  
 
Using the modified ABC-like classification, cases with positive MUM1/IRF4 or FOXP1 
expression were considered to belong to the ABC-like subgroup, whereas the rest of cases 
were assigned as others (Figure 5). 
 






7.5 Statistical methods 
Statistical analyses were carried out using Statistical software package SPSS version 11.0 
for Macintosh and version 14.0 for Windows (SPSS, Chicago, IL, USA).  
 
To analyse the difference in frequencies of patient characteristics and predictive factors, 
Chi-square test was used. Reproducibility of immunohistochemical stainings was 
evaluated by Kappa value. Survival rates were estimated by the Kaplan-Meier method, 
and the differences were compared by the log rank test. Cox univariate and multivariate 
analyses were carried out to evaluate the prognostic impact of clinical and molecular 
factors on survival, acknowledging also the relative risk and 95% confidence intervals 
(CI). All p-values were 2-tailed, and a probability value of less than 0.05 was considered 
significant. OS was estimated as the time from diagnosis to death of any cause or to the 
date of the last follow-up. Failure-free survival (FFS) was determined as the time from 


























8. RESULTS  
8.1 Expression of germinal centre B-cell-like (GCB)- and activated B-
cell-like (ABC)-associated markers   
The expression of the GCB- and ABC-associated markers is presented in Table 7. The 
samples were CD10-, BCL6-, MUM1/IRF4-, BCL2- and FOXP1-positive in 
approximately 36%, 58%, 51%, 67% and 19% of cases, respectively. The cut-off 
percentages used in the survival analysis were the same in each study.  
 
 
Table 7. Expression of cell-of-origin-associated proteins in DLBCL samples. 
 STUDY I STUDY II STUDY III STUDY IV 







































































8.2 Prognostic impact of Hans algorithm-based cell-of-origin 
classification on survival (I, II) 
In these series, the immunohistochemically defined GCB and non-GCB phenotypes were 
determined for all patients based on the expression of CD10, BCL6 and MUM1/IRF4 






8.2.1 Outcome in immunochemotherapy-treated DLBCL patients (I) 
Clinical characteristics 
Baseline and treatment characteristics of 90 immunochemotherapy-treated patients and 
104 controls treated with an antracyclin-based, CHOP-like chemotherapy regimen were 
compared. The patient and clinical characteristics were well balanced between the groups. 
According to IPI, 60% of subjects in the rituximab group and 63% in the control group 
had a low-risk disease, with an Ann Arbor stage of III or IV in 73% and 68% of cases, 
respectively.  
 
The immunochemotherapy group consisted of 56% GCB and 44% non-GCB patients. The 
distribution was comparable in the chemotherapy group, as the GCB phenotype was 
observed in 45% and non-GCB phenotype in 55% of cases (p=0.200). The 
immunohistochemically defined non-GCB group included more males than females 
compared with the GCB subgroup. No significant differences in age, Ann Arbor stage and 
IPI score were observed between phenotypes or treatments. 
 
Survival analysis 
To analyse the survival of DLBCL patients in the pre- and post-rituximab eras, we 
compared the outcome of the immunochemotherapy and control groups. At 2 years, a 
significant difference in FFS and OS emerged between the groups. The FFS was 69% in 
the rituximab group and 45% in the control group. The corresponding OS rates were 79% 
and 61%. These survival differences were further observed in supplementary analysis in 
all age and IPI subgroups. A complete response was achieved after treatment in 70% of 
the patients in the rituximab group and in 79% of patients in the control group (p=0.250).  
 
According to the IPI, the series consisted of about 60% low-risk and intermediate-risk (IPI 
0-2) patients. The low-risk patients showed a significantly better survival than the high-
risk (IPI 3-5) patients. In the rituximab group, the 2-year FFS was 79% for low-risk and 
56% for high-risk patients (p=0.028), and the corresponding 2-year OS was 88% and 67% 
(p=0.030). Similar differences in the survival were observed in the control group (FFS 
57% vs. 26%, p=0.001, and OS 75% vs. 39%, p<0.001). Cox multivariate analysis 
confirmed IPI as an independent prognostic factor for FFS and OS in chemotherapy- and 
immunochemotherapy-treated patients. 
 
Consistent with previous studies (Hans et al. 2004, Berglund et al. 2005), chemotherapy-
treated patients with the GCB phenotype had a significantly better survival than those with 
the non-GCB phenotype (FFS 59% vs. 34%, p=0.001, and OS 73% vs. 51%, p=0.012). 






no difference in survival was observed between the molecular subgroups (FFS 72% vs. 
67%, p=0.593, and OS 77% vs. 82%, p=0.936). In the rituximab group, the adverse impact 
of the non-GCB phenotype was eliminated.   
8.2.2 Outcome in DLBCL patients treated with ASCT-supported HDT (II) 
Clinical characteristics 
Twenty-nine young high aa-IPI patients treated with HDT and ASCT, and 34 
chemotherapy-treated control patients showed no difference in median age (ASCT 44.4 
years and controls 52.5 years) or gender (ASCT: male 52%, female 48%, and controls: 
male 53%, female 47%). The ASCT group consisted of 93% high-risk patients according 
to the aa-IPI, whereas in the control group only 59% of patients had a high-risk disease 
(p=0.003). However, no significant difference was observed for Ann Arbor stage in the 
groups. Distribution of the immunophenotypes was equal. In the ASCT group, 45% of the 
patients belonged to the GCB and 55% to the non-GCB phenotype. In the control group, 
the corresponding division was 56% and 44%.  
 
Survival analysis 
The 2-year FFS rate was 64% in the ASCT group and 46% in the control group (p=0.020). 
In OS, a trend for a superior outcome was observed in patients treated with ASCT relative 
to the chemotherapy-treated patients (75% vs. 63%, p=0.183). According to the aa-IPI, 
high-risk patients had a worse outcome than low-risk patients, but due to the small number 
of low-risk patients the difference in survival remained non-significant. 
 
To evaluate the impact of treatment on the predictive value of immunophenotype, we 
analysed the survival according to GCB and non-GCB subtypes. In the chemotherapy-
treated group, non-GCB cases had a very poor survival relative to GCB patients (FFS 20% 
vs. 66%, p<0.001, and OS 47% vs. 77%, p=0.004). Conversely, no difference in outcome 
was observed between GCB and non-GCB patients treated with HDT and ASCT (FFS 
67% vs. 62%, p=0.804, and OS 83% vs. 61%, p=0.585). We further compared the 
outcomes to evaluate the effect of treatment on the predictive value of the phenotype. 
According to phenotype and treatment, no significant difference in survival was present in 
GCB patients after ASCT or chemotherapy treatment (FFS 67% vs. 66%, p=0.821, and 
OS 83% vs. 77% p=0.414). However, in non-GCB patients, the ASCT-treated subgroup 
had a significantly better outcome than the control group (FFS 62% vs. 20%, p<0.001, and 
OS 69% vs. 47%, p=0.009). Cox regression analysis confirmed the prognostic value of 
treatment in non-GCB patients (FFS: RR 0.094, 95% CI 0.031-0.285, p<0.001, and OS: 






Table 8. Association of IPI and cell-of-origin phenotype on survival.  
DLBCL patients treated 

















All 90 82 69  89 79  
IPI 
     low 0-2  

















Hans algorithm        
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DLBCL patients treated 

















All 104 61 45  80 61  
IPI (missing 1) 
     low 0-2  

















Hans algorithm        
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DLBCL patients treated 

















All 29 86 64  93 75  
Hans algorithm        
     GCB 

















DLBCL patients treated 

















All 34 56 46  82 63  
Hans algorithm        
     GCB 























8.3 Markers associated with ABC phenotype (III) 
Clinical characteristics 
In Study III, a group of 117 R-CHO(E)P treated de novo DLBCL patients was analysed. 
Approximately two-thirds of the patients had disseminated stage III or IV disease, and 
39% had high IPI (3-5) risk scores.  
 
A high BCL2 immunoreactivity was observed in 78 lymphomas (67%), whereas 39 cases 
were negative. The expression of BCL2 was associated with the non-GCB phenotype 
(p=0.011). No relationship was observed between BCL2 and FOXP1 expression.  
 
The expression of FOXP1 was scored positive if 100% of the lymphoma cells had a 
uniform strong nuclear expression. Twenty-two (19%) of the lymphomas stained strongly 
for FOXP1, whereas the remaining 95 cases were negative. Distribution of FOXP1 
immunoreactivity was comparable with a previous study (Barrans et al. 2004). We also 
evaluated the cut-off level of 30% for FOXP1-positive lymphoma cells (positive 39 
(33%), negative 78 (67%)), observing no difference in outcome relative to the 100% cut-




The estimated 3-year FFS and OS rates were 71% and 80% for all patients, respectively. 
When the survival was analysed according to IPI risk stratification, low-risk patients had 
an improved outcome relative to high-risk patients (FFS 86% vs. 49%, p=0.001 (Figure 
6A), and OS 89% vs. 69%, p=0.027). The division of the patients by cell-of-origin 
distinction according to the Hans algorithm showed no difference in outcome between 
GCB and non-GCB cases (FFS 76% vs. 67%, p=0.157, and OS 82% vs. 79%, p=0.636).  
 
The results of this study further showed that BCL2 had prognostic value in this patient 
cohort. According to the Kaplan-Meier analysis, a worse outcome was observed after R-
CHO(E)P treatment for BCL2-positive than for BCL2-negative patients. The 3-year FFS 
was 86% for BCL2-negative patients and 61% for BCL2-positive patients (p=0.001) 
(Figure 6B). A significantly difference in OS was also observed (negative 86% vs. 
positive 76%, p=0.034).  
 
The predictive impact for BCL2 on outcome was further analysed separately in the GCB 






of BCL2 on 3-year FFS (negative 100% vs. positive 58%, p=0.011) and a trend for a 
difference in OS (negative 100% vs. positive 74%, p=0.082) were observed. By contrast, 
in GCB patients, BCL2 expression had no significant prognostic impact on survival (FFS, 
negative 85% vs. positive 68%, p=0.076, and OS, negative 85% vs. positive 78%, 
p=0.225). 
 
The prognostic role of BCL2 was further confirmed in Cox analyses. According to 
univariate analyses, both IPI and BCL2 had a significant prognostic impact. In 
multivariate analyses, BCL2 remained an independent prognostic factor for FFS, but not 
for OS (FFS: RR 4.965, 95% CI 1.091-22.601, p=0.038, and OS: RR 3.592, 95% CI 
0.820-15.736, p=0.090). 
 
FOXP1 expression did not predict outcome in immunochemotherapy-treated patients. The 
3-year FFS was 65% for FOXP1-positive and 72% for FOXP1-negative patients 






























8.4 Prognostic impact of modified cell-of-origin algorithms (IV) 
Clinical characteristics 
Both IPI and R-IPI were retrospectively determined for the 88 R-CHOP-treated patients. 
Sixty-two percent had a low-risk disease according to IPI (IPI 0-2), whereas the remaining 
patients had a high-risk disease (IPI 3-5). According to the R-IPI risk stratification, 7%, 
55% and 38% of patients had very good, good and poor prognosis, respectively. Of the 
patients, 49% had involvement of one or more extranodal sites at the time of diagnosis, 
and 53% had advanced stage III or IV disease.  
 
Survival analysis 
For all patients, the 3-year FFS was 72% and the OS 77%. According to the IPI and R-IPI 
risk stratifications, a significant difference in survival rates was present. The FFS was 84% 
for IPI low-risk and 53% for IPI high-risk patients (p=0.002). The difference in OS was 
similar (IPI low-risk 85% vs. IPI high-risk 63%, p=0.012). Concordantly, the R-IPI 
distinguished three risk groups with different outcomes, FFS 100%, 82% and 53% for 
very good, good and poor risk groups, respectively. The corresponding OS rates observed 
in the R-IPI risk groups were 100%, 83% and 63%. No difference in outcome emerged 
between patients with nodal and those with extranodal involvement.  
8.4.1 Modified ABC-like classification and other classifications 
In the patient cohort, MUM1/IRF4 expression was observed in 43 patients and FOXP1 
expression in 16 patients. According to the modified ABC-like classification, 46 cases 
were assigned to the ABC-like subgroup and the remaining 42 cases to the subgroup of 
“others”.  The classification correlated significantly with CD10 (p<0.001) and BCL6 
expression (p=0.001), and Hans (p<0.001) and Muris algorithms (p<0.001). The rate of 
misclassification in relation to the Hans algorithm was 14% and in relation to the Muris 
algorithm 16%. The measure of agreement between the modified ABC-like and Hans 
classifications was 0.727.  
 
Clinical characteristics were well balanced between the subgroups. The ABC-like 







According to Kaplan-Meier analysis, the ABC-like subgroup had a significantly inferior 
FFS rate (63% vs. 82%, p=0.048) (Figure 7A). For patients with the ABC-like phenotype, 
a trend for an adverse OS was also observed (69% vs. 85%, p=0.110). 
 
According to the Muris algorithm, group 2 consisted of 32 patients with the post-GCB 
immunophenotype. The rest of the patients (64%) belonged to group 1. Patients in group 2 
showed an adverse outcome relative to patients in group 1. The FFS was 59% in group 2, 
compared with 81% in group 1 (p=0.041) (Figure 7B), and the corresponding OS was 
67% and 82% (p=0.159). 
 
When the cell of origin was determined using the Hans algorithm, 48% of cases belonged 
to the GCB subgroup and the remainder had the non-GCB phenotype. The differences in 
clinical outcomes between the GCB and non-GCB patients were non-significant (FFS 75 
























Figure 7. Failure-free survival according to A) modified ABC-like algorithm, B) Muris algorithm 













Table  9. Association of IPI, BCL2, FOXP1 and cell-of-origin phenotype on survival. 
DLBCL patients treated 

















All 117 89 71  93 80  
IPI (missing 1) 
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9.1 Immunohistochemically defined cell-of-origin distinction in DLBCL 
(I, II) 
The addition of rituximab to conventional chemotherapy has significantly improved the 
outcome of DLBCL patients during the last decade. Currently, the IPI risk stratification is 
the only prognostic tool in use in daily clinical practice. However, our knowledge of the 
biology of DLBCL has significantly improved from the findings attained in GEP studies. 
As the cell of origin identified by either the GEP (Alizadeh et al. 2000) or IHC (Hans et al. 
2004) methodology was observed to be prognostic for patients treated with chemotherapy, 
we decided to identify the prognostic role of the GCB and non-GCB phenotypes in 
immunochemotherapy-treated patients. When this study commenced, no analyses of cell-
of-origin distinction in rituximab-treated patients had been published. In Study I, we 
observed that according to the Hans algorithm the IHC-defined GCB patients had 
improved survival relative to non-GCB patients treated with chemotherapy. This finding 
was consistent with previous studies (Hans et al. 2004, Berglund et al. 2005). By contrast, 
the prognostic value of the cell-of-origin distinction disappeared in patients treated with a 
combination of rituximab and chemotherapy. In both treatment groups, only the IPI risk 
stratification could distinguish between patients with good and poor prognosis. 
 
In the studies subsequently published in the immunochemotherapy era, the results on the 
prognostic impact of GCB and non-GCB phenotype have been controversial. Consistent 
with our findings, several studies have not observed any difference in survival between 
GCB and non-GCB patients treated with immunochemotherapy (Saito et al. 2007a, 
Ennishi et al. 2008, Uccella et al. 2008, Wilson et al. 2008, Copie-Bergman et al. 2009, 
Ilic et al. 2009, Kyllönen et al. 2009, Seki et al. 2009, Song et al. 2009, Xia et al. 2010). 
The immunochemotherapy regimen has consisted of rituximab in combination with 
CHOP-like chemotherapy. However, Fu et al. (2008) reported that in a series of both 
EPOCH- and R-EPOCH-treated DLBCL patients, OS was significantly better for the 
group of GCB patients than in patients with the non-GCB phenotype. With the EFS, a 
significant difference was observed in chemotherapy-treated patients, whereas only a trend 
for a difference was seen in immunochemotherapy-treated patients. In addition, in an 
immunochemotherapy-treated Japanese cohort, superior survival was observed for GCB 







In Study II, we evaluated the clinical impact of immunophenotyping in DLBCL patients 
treated with HDT supported with ASCT and noted that the survival was similar for the 
GCB and non-GCB subgroups. Other subsequent studies (Veelken et al. 2007, Costa et al. 
2008, Hallack Neto et al. 2009a) have also reported that GCB and non-GCB DLBCL 
patients had a similar survival after HDT and ASCT, and that the outcome was 
independent of cell-of-origin distinction. On the other hand, the trials of the Dutch 
Hemato-Oncology Association (HOVON) for poor-risk DLBCL patients showed that the 
GCB phenotype had a significant positive impact on survival relative to the non-GCB 
phenotype (van Imhoff et al. 2006). However, rituximab was not included in the treatment 
regimens in these studies.  
 
Our results in Studies I and II revealed that the survival of all DLBCL patients, but 
particularly non-GCB patients, improved in response to modification of conventional 
chemotherapy. Those lymphomas that relapsed after intensified treatments were most 
refractory to salvage therapies, and the patients died rapidly due to lymphoma. The 
mechanism by which non-GCB patients benefit more from intensified regimens than GCB 
patients is unknown, but is likely to be associated with biological features of the disease.  
 
The biological characteristics related to aggressive disease in ABC-type DLBCLs include 
defective apoptosis signalling caused by overexpression of the anti-apoptotic BCL2, high 
expression of NF-κB and constitutive activation of Iκ kinase (Davis et al. 2001, 
Rosenwald et al. 2002, Iqbal et al. 2004, Bea et al. 2005, Lam et al. 2005). By contrast, the 
BCL6 gene is principally expressed in GCB DLBCLs (Alizadeh et al. 2000, Rosenwald et 
al. 2002, Wright et al. 2003).  
 
NF-κB is an important mediator of resistance to apoptosis. Lymphoma cells with 
constitutively active NF-κB have been observed to be resistant to chemotherapeutic 
agents, and inhibition of NF-κB to increase the sensitivity of lymphoma cells to therapy in 
vitro (Wang et al. 1999). The induced cell cycle arrest and apoptosis by inhibition of NF-
κB are mainly seen in cell lines representing ABC-type lymphomas, suggesting that this 
particular mechanism could contribute to the poor outcome of these lymphomas (Davis et 
al. 2001). Rituximab, on the other hand, may control the NF-κB pathway and play a role 
in the sensitization of lymphomas to chemotherapeutic agents. Rituximab has been 
observed to inhibit expression of the components of the NF-κB pathway, consequently 
decreasing the activity of the pathway in chemoresistant DLBCL cell lines (Jazirehi et al. 
2005). This may provide a survival benefit for the non-GCB subgroup. As rituximab 
decreases the activity of the NF-κB pathway, the expression of the NF-κB target gene 






also reduced (Liu et al. 2007). Liu et al. (2007) observed that expression of PRDM1β 
correlated with poor outcome in chemotherapy-treated non-GCB patients. However, the 
addition of rituximab eliminated the survival difference, further supporting the more 
beneficial effect of rituximab in non-GCB patients. The NF-κB pathway was also noted to 
induce the expression of cytokines IL-6 and IL-10 through the signal transducer and 
activator of transcription (STAT) 3 protein signalling in ABC DLBCLs (Lam et al. 2008), 
although the consequences of this action remain unclear. Furthermore, in studies 
performed with DLBCL and other B-cell lymphoma cell lines, rituximab has been 
described to inhibit the constitutively active phosphatidylinositol-3-kinase/AKT 
(PI3K/AKT) (Smith et al. 2005, Uddin et al. 2006, Suzuki et al. 2007), mitogen-activated 
protein kinase kinase 1/2 (MAPK) (Vega et al. 2004) and extracellular signal-regulated 
kinase 1/2 (ERK) pathways (Jazirehi et al. 2004), but the impact of these pathways on the 
outcome of DLBCL patients still needs to be clarified. 
 
The association of GCB phenotype with a more favourable outcome may be a 
consequence of the expression of BCL6 since BCL6 represses the expression of the 
PRDM1 gene (Shaffer et al. 2000, Tunyaplin et al. 2004), transcription of NFκB1 (Li et al. 
2005) and activity of NFκB (Perez-Rosado et al. 2008). The GCB DLBCLs also show 
prominent levels of pro-apoptotic molecules Bax, Bak and Bid, possibly contributing to 
the good response to therapy (Bai et al. 2004). IL-4 target genes have been observed to be 
differentially expressed in the GCB and non-GCB subgroups (Lu et al. 2005), and IL-4 
can sensitize the GCB cells to chemotherapy and rituximab (Sarosiek et al. 2009).   
 
It is, however, important to note that the identified biological characteristics of GCB and 
non-GCB lymphomas have not yet clarified the controversial findings obtained in studies 
of the prognostic impact of immunohistochemically defined cell-of-origin distinction for 
survival. These clinical and methodological factors that may influence the results will be 
discussed further in the following section. 
9.2 Markers and algorithms associated with the ABC phenotype (III, IV) 
Since the immunohistochemical findings of the prognostic impact of the cell of origin for 
survival were conflicting, we decided to evaluate other markers and alternative algorithms, 
predominantly associated with the ABC phenotype. We focused on the expression of 
MUM1/IRF4, FOXP1 and BCL2 in immunochemotherapy-treated de novo DLBCL 
patients. Although the studies were retrospective, we aimed to minimize treatment-related 






Before the initiation of our study, the prognostic impact of FOXP1 had not been evaluated 
in immunochemotherapy-treated DLBCL patients. Moreover, the results concerning the 
predictive value of BCL2 expression had been controversial. In Study III, the expression 
of FOXP1 and BCL2 proteins was found to be associated with the non-GCB phenotype. 
This finding is consistent with previous studies on chemotherapy-treated patients (Barrans 
et al. 2004, Hans et al. 2004, van Imhoff et al. 2006). In survival analysis, no difference 
was observed in the outcome between FOXP1-positive and -negative patients. The 
number of FOXP1-positive cases was relatively small (19%), possibly restricting the 
survival analyses. By contrast, BCL2-negative patients had a significantly better outcome 
than BCL2-positive patients, both among all patients and especially in the non-GCB 
subgroup. Consistent with our findings, BCL2 negativity at the mRNA and protein levels 
has been reported to be a favourable feature in immunochemotherapy-treated patients 
(Malumbres et al. 2008, Winter et al. 2008). Similarly, when the BCL2 expression was 
evaluated separately in the GCB and non-GCB subgroups, the BCL2 expression was 
predictive in GCB patients treated with immunochemotherapy, and patients with the 
BCL2-negative GCB phenotype had the most favourable prognosis (Song et al. 2009). In 
other studies, addition of rituximab to chemotherapy resulted in a loss of the negative 
prognostic impact of BCL2 on survival (Mounier et al. 2003, reviewed in Shivakumar & 
Armitage 2006, Wilson et al. 2007, Fu et a. 2008, Wilson et al. 2008, Seki et al. 2009, 
Song et al. 2009). 
 
BCL2 is a regulator of apoptosis and its overexpression has been observed to result in 
chemotherapy resistance of lymphoma cells both in vitro and in vivo (Hermine et al. 1996, 
Kramer et al. 1998, Barrans et al. 2002). Rituximab, on the other hand, induces apoptosis 
and sensitizes lymphoma cells to chemotherapeutic agents by downregulating BCL2 and 
BCL-xL expression (Alas & Bonavida 2001, Jazirehi et al. 2003). The results of studies in 
cell culture indicate that rituximab could eradicate the negative impact of BCL2 
expression on survival. Additionally, rituximab was observed to inhibit IL10 (Alas & 
Bonavida 2001, Alas et al. 2001), which functions as a regulator of BCL2 (Voorzanger et 
al. 1996, Weber-Nordt et al. 1996), and to consequently interfere with the expression of 
BCL2. However, interactions between BCL2 and IL10 gene polymorphisms have recently 
been described to cause R-CHOP resistance in DLBCLs (Park et al. 2009). Furthermore, 
in lymphomas with BCL2 and MYC translocations, patients negative for BCL2 expression 
have been reported to have a significantly superior survival relative to BCL2-positive 
patients (Johnson et al. 2009). Thus, multiple details of the lymphoma genome complicate 







In Study IV, we focused on ABC-associated markers. We evaluated MUM1/IRF4 and 
FOXP1 positivities and developed a modified ABC-like classification. As a result, we 
were able to distinguish the ABC-like subgroup of DLBCL patients with poor survival in 
response to immunochemotherapy. Similarly, according to the Muris classification based 
on the expression of BCL2, CD10 and MUM1/IRF4, the group of BCL2-positive post-
GCB patients had an inferior survival relative to the other patients. Although a correlation 
existed in the phenotypes identified by the modified ABC-like classification and the Hans 
algorithm, no survival difference was observed between GCB and non-GCB patients when 
the Hans algorithm was used. The difference in the prognostic impact between the 
separate algorithms may be associated with BCL6 immunostaining. In the Hans algorithm, 
BCL6 has an effect on the classification of the phenotype in about 70% of CD10-negative 
DLBCLs. There is a risk for misclassification of these DLBCLs, as a poor reproducibility 
of BCL6 staining and interpretation of immunoreactivity have been found (de Jong et al. 
2009). 
 
Consistent with our findings in the immunochemotherapy era, Sjö et al. (2007) had 
previously confirmed the prognostic value of the Muris algorithm in chemotherapy-treated 
DLBCL patients. Similarly, the value of the modified ABC-like classification needs to be 
further tested in other patient cohorts and prospective studies. Nevertheless, confirmatory 
results of the negative impact of FOXP1 and MUM1/IRF4 expression on survival were 
recently reported. An immunofluorescence in situ (FISH) index, defined by two of the 
three ABC markers (positivity for FOXP1, MUM1/IRF4 or BCL6 breakpoint), was 
observed to be associated with an unfavourable outcome in immunochemotherapy-treated 
DLBCL patients (Copie-Bergman et al. 2009).  
 
The benefit of the proposed algorithms in DLBCL is their ability to define the subgroups 
based on only two to five markers. However, the algorithms are dependent on the 
prognostic effect of each marker as well as its hierarchical position in the algorithm. For 
example, if a staining is unreliable and difficult to score, the algorithm may not classify 
the subgroups correctly. Furthermore, diverse routine practices in different centres may 
influence the results obtained with algorithms.  
9.3 Clinical and methodological variables that determine the predictive 
value of molecular markers in DLBCL (IV) 
GEP-based measurement of mRNA levels in lymphomas identified molecular 






technique is currently not available for routine clinical use due to lack of standardized 
commercially accessible tests. The requirement for fresh or frozen tissue samples also 
limits the methodology. Although RNA has been extracted from paraffin blocks, this 
methodology is rarely feasible. Immunohistochemical class prediction and determination 
of prognostic markers, in turn, would be more practical. To date, unfortunately, the 
reported IHC-defined results have been inconsistent. A number of clinical and 
methodological factors are likely to account for the variable results. Clinical factors 
include patient and treatment-related characteristics. Methodological factors are related to 
the immunohistochemical method and include variations in techniques, scoring criteria 
and inter-and intraobserver variability.    
9.3.1 Clinical variables 
Selection of patient series varies in different studies. The cohorts are either retrospectively 
or prospectively collected. The specific age groups, distribution of gender, populations, 
and possible inclusion of relapsed patients in the studies may also create biases. 
Furthermore, survival of the patients may be affected by the involvement of nodal or 
extranodal regions, as those with local lymphomas have a more favourable outcome than 
patients with a disseminated disease. The chemotherapy regimens used in different 
countries are globally observed to be non-uniform, mostly due to historical routines. Also, 
during the time period when rituximab treatment was initiated and the 
immunochemotherapy era started, there were several treatment options. Likewise, the OS 
may be influenced by the effective second-line treatment (rituximab, HDT and ASCT, or 
palliative treatment) in patients who relapse after first-line treatment. 
 
Currently, potential new treatment approaches are under investigation in lymphomas. 
Novel therapies, including biological drugs, may have an effect on the prognostic impact 
of all of the factors studied thus far in DLBCL. When new treatments are applied in 
therapy routines, the previously recognized prognostic markers require reassessment. As 
well with new therapies, other previously unidentified biological factors of DLBCL may 
play an important role in prognosis.  
 
Potential future treatments in DLBCL include radioimmunotherapy, which has already 
become an option in FL and mantle cell lymphoma. 90Y-ibritumumabtiuxetan targets 
radiation to B-lymphoma cells by CD20 guidance. The response rates observed for 90Y in 
phase I/II trials are approximately 50% for DLBCL patients (Witzig et al. 1999, Gordon et 
al. 2004). Other phase II/III studies have been performed to evaluate the use of 






for HDT and ASCT (Morschhauser et al. 2007), as well as following CHOP as a 
consolidation therapy in previously untreated elderly patients (Zinzani et al. 2008), with 
promising results. Furthermore, the second generation of anti-CD20 antibodies 
(veltuzumab, ofatumumab), with structural and functional differences to rituximab, has 
been created to improve the efficacy of treatments. Results in phase I/II studies of 
veltuzumab in relapsed and refractory B-cell NHLs show good tolerability of the drug and 
promising objective responses (Morschhauser et al. 2009), which will be further evaluated 
in ongoing clinical trials. Biologically designed therapies with indications in other cancer 
entities are also under investigation in DLBCL. Results are expected from ongoing phase 
3 trials, after initial results on the VEGF-A antibody bevacizumab (Stopeck et al. 2009), 
the PKCβ inhibitor enzastaurin (Robertson et al. 2007) and the mammalian target of the 
rapamycin (mTOR) inhibitor everolimus (Yee et al. 2006).  
9.3.2 Methodological variables 
Incorporation of IHC-defined predictive markers into clinical practice is not yet 
appropriate, partly due to the lack of validation of the methodology. Variation in 
laboratory techniques is related to differences in the use of TMA or whole-tissue sections, 
fixation of slides, staining protocols, and use of different antibodies. The TMA technique 
allows simultaneous staining and analysis of a large number of tumours, but in some cases 
cores can be missing. Debatable is also the representativeness of a TMA sample compared 
with a whole-tissue section, as the architecture of the lymphoma may be indistinctive in 
the TMA cores. According to a report by Hedvat et al. (2002), the TMA was comparable 
with whole sections in IHC analysis of several commonly used markers of NHL such as 
CD10, CD20 and BCL2. However, determination of the GCB phenotype from TMA 
sections was unreliable due to difficulties in the scoring of BCL6 on TMAs relative to 
whole-tissue sections (Linderoth et al. 2007a). Scoring of the data also diverges, as 
different cut-off levels are used. The cut-off levels are often determined according to 
previous data or, for example, as the median positive value of the staining. For instance, 
the cut-off level of the markers in the Hans algorithm was generally determined as more 
than 30% positivity of the lymphoma cells (Hans et al. 2004, Berglund et al. 2005, Amen 
et al. 2007), but in other studies variations in the cut-off level - between 10% and 50% - 
have been used (Muris et al. 2006, Veelken et al. 2007). The positivity of a staining is 
usually determined by one or two pathologists. The result is therefore dependent on the 
knowledge of the pathologist, leading to a risk for bias. This problem could probably be 







In 2003, the Lunenburg Lymphoma Biomarker Consortium was established as an 
international collaboration in order to unify IHC methods in biomarker research. Thus far, 
the group has focused on standardization of measurements and validation of the 
prognostic relevance of biomarkers in DLBCL (de Jong et al. 2007 & 2009). They have 
especially concentrated on technical and intra-observer variations in scoring interpretation. 
The study included eight experienced laboratories that used diverse protocols and 
antibodies in the stainings of eight proteins on identical TMAs. Although the same 
antibody clone was used, staining intensities were noted to differ significantly, and 
technical artefacts were also observed. After eliminating the discrepancies in the stainings, 
the scorings were evaluated by nine pathologists. The reproducibility was excellent or 
very good for several markers, i.e. CD10, CD20, MUM1/IRF4, CD5 and BCL2. However, 
poor reproducibility was noted for Ki-67 and BCL6. Initially, the agreement observed for 
the classification of GCB and non-GCB was 57%, but after optimizing the stainings the 
agreement improved to 77% (de Jong et al. 2009). The IHC for subclassification of 
DLBCL was reported to be feasible. The intra- and interobserver variation for BCL2 has 
also been evaluated and determined to be acceptable in assessments of lymphoma (Borlot 
et al. 2008).  
 
A goal of future studies will be to analyse both RNA and tissue samples by collecting both 
frozen and fresh, and paraffin-embedded materials from all patients. In research and in 
clinical practice, the immunohistochemical technique needs to be optimized and the 
scoring criteria strictly followed. Later, by combining several markers in different samples 
of a patient and by using diverse techniques and methods (i.e. tissue and serum samples, 
IHC and in situ hybridization), the reliability and value of predictive markers should 
improve. The molecular properties of DLBCL will likely tailor treatment decisions in the 
future, as demonstrated by the proteasome inhibitor bortezomib, which enhances the 







Diversity in its clinical presentation, morphology and immunophenotype indicate that 
DLBCL is a heterogeneous disease. GEP studies have contributed to improved knowledge 
of the molecular features of DLBCL. In addition to tumour-specific divergences, crosstalk 
between tumour cells and the microenvironment might also be important. Currently, GEP 
is not accessible in routine clinical use. However, identification of the molecular 
phenotypes and markers has been translated to an applicable approach by using IHC. 
 
In these studies, we evaluated the prognostic impact of IHC-defined molecular markers 
and algorithms in DLBCL patients treated with immunochemotherapy or HDT and ASCT. 
The main conclusions were as follows: 
 
1. The prognostic impact of the Hans algorithm cell-of-origin classification, based on the 
expression of CD10, BCL6 and MUM1/IRF4, is eliminated in DLBCL patients treated 
with immunochemotherapy. Correspondingly, the GCB and non-GCB high-risk 
patients treated with HDT and ASCT have a similar survival. 
 
2. In immunochemotherapy-treated DLBCL patients, BCL2 negativity is associated with 
superior survival. By contrast, FOXP1 expression does not have a prognostic impact 
on survival. 
 
3. Modified algorithms primarily focusing on ABC-associated markers identify the ABC-
like subgroup of DLBCL patients with a poor prognosis after immunochemotherapy.  
 
Although our results suggest that the proposed modified ABC-like classification and the 
expression of BCL2 may identify DLBCL patients with an unfavourable outcome, these 
findings need to be re-evaluated in prospective studies. Knowledge about the biology of 
DLBCL in combination with the clinical features of the disease will hopefully define 
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